US6528624B1
(en)
|
1998-04-02 |
2003-03-04 |
Genentech, Inc. |
Polypeptide variants
|
US7183387B1
(en)
|
1999-01-15 |
2007-02-27 |
Genentech, Inc. |
Polypeptide variants with altered effector function
|
NZ539776A
(en)
*
|
1999-01-15 |
2006-12-22 |
Genentech Inc |
Polypeptide variants with altered effector function
|
US6737056B1
(en)
*
|
1999-01-15 |
2004-05-18 |
Genentech, Inc. |
Polypeptide variants with altered effector function
|
JP4992068B2
(ja)
*
|
2000-01-27 |
2012-08-08 |
メディミューン,エルエルシー |
超高親和性中和抗体
|
CA2401652A1
(en)
|
2000-03-01 |
2001-09-07 |
Medimmune, Inc. |
High potency recombinant antibodies and method for producing them
|
US7179900B2
(en)
*
|
2000-11-28 |
2007-02-20 |
Medimmune, Inc. |
Methods of administering/dosing anti-RSV antibodies for prophylaxis and treatment
|
US6855493B2
(en)
|
2000-11-28 |
2005-02-15 |
Medimmune, Inc. |
Methods of administering/dosing anti-RSV antibodies for prophylaxis and treatment
|
EP2357187A1
(de)
*
|
2000-12-12 |
2011-08-17 |
MedImmune, LLC |
Moleküle mit längeren Halbwertszeiten, Zusammensetzungen und deren Verwendung
|
US7658921B2
(en)
*
|
2000-12-12 |
2010-02-09 |
Medimmune, Llc |
Molecules with extended half-lives, compositions and uses thereof
|
US20040002587A1
(en)
*
|
2002-02-20 |
2004-01-01 |
Watkins Jeffry D. |
Fc region variants
|
US20080254027A1
(en)
*
|
2002-03-01 |
2008-10-16 |
Bernett Matthew J |
Optimized CD5 antibodies and methods of using the same
|
US20080260731A1
(en)
*
|
2002-03-01 |
2008-10-23 |
Bernett Matthew J |
Optimized antibodies that target cd19
|
US8188231B2
(en)
|
2002-09-27 |
2012-05-29 |
Xencor, Inc. |
Optimized FC variants
|
US20040132101A1
(en)
*
|
2002-09-27 |
2004-07-08 |
Xencor |
Optimized Fc variants and methods for their generation
|
US7317091B2
(en)
*
|
2002-03-01 |
2008-01-08 |
Xencor, Inc. |
Optimized Fc variants
|
US7662925B2
(en)
*
|
2002-03-01 |
2010-02-16 |
Xencor, Inc. |
Optimized Fc variants and methods for their generation
|
US20100311954A1
(en)
*
|
2002-03-01 |
2010-12-09 |
Xencor, Inc. |
Optimized Proteins that Target Ep-CAM
|
US20090042291A1
(en)
*
|
2002-03-01 |
2009-02-12 |
Xencor, Inc. |
Optimized Fc variants
|
US20070122406A1
(en)
|
2005-07-08 |
2007-05-31 |
Xencor, Inc. |
Optimized proteins that target Ep-CAM
|
US20070148171A1
(en)
*
|
2002-09-27 |
2007-06-28 |
Xencor, Inc. |
Optimized anti-CD30 antibodies
|
US20050152899A1
(en)
*
|
2002-05-10 |
2005-07-14 |
Kinch Michael S. |
EphA2 agonistic monoclonal antibodies and methods of use thereof
|
ATE530577T1
(de)
*
|
2002-05-10 |
2011-11-15 |
Purdue Research Foundation |
Epha2 agonistische monoklonale antikörper und deren anwendungsverfahren
|
EP1519956B1
(de)
*
|
2002-05-10 |
2011-09-21 |
Medimmune, Inc. |
Epha2 monoklonale antikörper und deren anwendungsverfahren
|
US7425618B2
(en)
*
|
2002-06-14 |
2008-09-16 |
Medimmune, Inc. |
Stabilized anti-respiratory syncytial virus (RSV) antibody formulations
|
US7132100B2
(en)
|
2002-06-14 |
2006-11-07 |
Medimmune, Inc. |
Stabilized liquid anti-RSV antibody formulations
|
US8946387B2
(en)
|
2002-08-14 |
2015-02-03 |
Macrogenics, Inc. |
FcγRIIB specific antibodies and methods of use thereof
|
US8968730B2
(en)
|
2002-08-14 |
2015-03-03 |
Macrogenics Inc. |
FcγRIIB specific antibodies and methods of use thereof
|
US20060235208A1
(en)
*
|
2002-09-27 |
2006-10-19 |
Xencor, Inc. |
Fc variants with optimized properties
|
US7365168B2
(en)
|
2002-10-15 |
2008-04-29 |
Pdl Biopharma, Inc. |
Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
|
DE60334141D1
(de)
|
2002-10-15 |
2010-10-21 |
Facet Biotech Corp |
VERÄNDERUNG VON FcRn-BINDUNGSAFFINITÄTEN ODER VON SERUMHALBWERTSZEITEN VON ANTIKÖRPERN MITTELS MUTAGENESE
|
US7361740B2
(en)
|
2002-10-15 |
2008-04-22 |
Pdl Biopharma, Inc. |
Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
|
US7217797B2
(en)
*
|
2002-10-15 |
2007-05-15 |
Pdl Biopharma, Inc. |
Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
|
CA2512729C
(en)
|
2003-01-09 |
2014-09-16 |
Macrogenics, Inc. |
Identification and engineering of antibodies with variant fc regions and methods of using same
|
US7960512B2
(en)
|
2003-01-09 |
2011-06-14 |
Macrogenics, Inc. |
Identification and engineering of antibodies with variant Fc regions and methods of using same
|
BRPI0406724A
(pt)
|
2003-01-13 |
2005-12-20 |
Macrogenics Inc |
Proteìna de fusão dimérica, métodos de tratar, prevenir ou melhorar um ou mais sintomas de um distúrbio autoimune e um ou mais sintomas de púrpura trombocitopênica idiopática, composição farmacêutica, ácido nucleico, vetor, célula hospedeira, método de produzir recombinantemente o polipeptìdeo, polipeptìdeo isolado, fragmento de qualquer um dos polipeptìdeos, e, molécula de ácido nucleico isolada
|
US8084582B2
(en)
|
2003-03-03 |
2011-12-27 |
Xencor, Inc. |
Optimized anti-CD20 monoclonal antibodies having Fc variants
|
US8388955B2
(en)
*
|
2003-03-03 |
2013-03-05 |
Xencor, Inc. |
Fc variants
|
US20090010920A1
(en)
|
2003-03-03 |
2009-01-08 |
Xencor, Inc. |
Fc Variants Having Decreased Affinity for FcyRIIb
|
JP4685764B2
(ja)
*
|
2003-04-10 |
2011-05-18 |
アボット バイオセラピューティクス コーポレイション |
変異誘発による抗体のFcRn結合親和力又は血清半減期の改変
|
EP1617864A4
(de)
*
|
2003-04-11 |
2006-06-21 |
Medimmune Inc |
Epha2 und nicht-neoplastische hyperproliferative zellstörungen
|
KR20110094361A
(ko)
*
|
2003-04-11 |
2011-08-23 |
메디뮨 엘엘씨 |
재조합 il9 항체 및 그의 용도
|
US9051373B2
(en)
|
2003-05-02 |
2015-06-09 |
Xencor, Inc. |
Optimized Fc variants
|
TWI353991B
(en)
|
2003-05-06 |
2011-12-11 |
Syntonix Pharmaceuticals Inc |
Immunoglobulin chimeric monomer-dimer hybrids
|
JP4667383B2
(ja)
*
|
2003-06-13 |
2011-04-13 |
バイオジェン・アイデック・エムエイ・インコーポレイテッド |
アグリコシル抗cd154(cd40リガンド)抗体およびその使用
|
JP4178514B2
(ja)
*
|
2003-06-27 |
2008-11-12 |
東洋紡績株式会社 |
抗体のスクリーニング方法
|
US20050106667A1
(en)
|
2003-08-01 |
2005-05-19 |
Genentech, Inc |
Binding polypeptides with restricted diversity sequences
|
AU2004266159A1
(en)
|
2003-08-22 |
2005-03-03 |
Biogen Idec Ma Inc. |
Improved antibodies having altered effector function and methods for making the same
|
EP1660094A4
(de)
|
2003-08-26 |
2009-09-16 |
Univ Colorado |
Hemmer der serinprotease-aktivität und ihre verwendung bei verfahren und zusammensetzungen zur behandlung von bakterieninfektionen
|
US8101720B2
(en)
|
2004-10-21 |
2012-01-24 |
Xencor, Inc. |
Immunoglobulin insertions, deletions and substitutions
|
US9714282B2
(en)
|
2003-09-26 |
2017-07-25 |
Xencor, Inc. |
Optimized Fc variants and methods for their generation
|
JP2007531707A
(ja)
*
|
2003-10-15 |
2007-11-08 |
ピーディーエル バイオファーマ, インコーポレイテッド |
IGの重鎖定常領域の位置250、314および/または428の変異誘発によるFc融合タンパク質血清半減期の改変
|
WO2005063815A2
(en)
*
|
2003-11-12 |
2005-07-14 |
Biogen Idec Ma Inc. |
Fcϝ receptor-binding polypeptide variants and methods related thereto
|
AU2004290070A1
(en)
|
2003-11-12 |
2005-05-26 |
Biogen Idec Ma Inc. |
Neonatal Fc receptor (FcRn)-binding polypeptide variants, dimeric Fc binding proteins and methods related thereto
|
WO2005077981A2
(en)
*
|
2003-12-22 |
2005-08-25 |
Xencor, Inc. |
Fc POLYPEPTIDES WITH NOVEL Fc LIGAND BINDING SITES
|
US7276585B2
(en)
*
|
2004-03-24 |
2007-10-02 |
Xencor, Inc. |
Immunoglobulin variants outside the Fc region
|
WO2005117967A2
(en)
|
2004-04-12 |
2005-12-15 |
Medimmune, Inc. |
Anti-il-9 antibody formulations and uses thereof
|
CN114053429A
(zh)
|
2004-06-01 |
2022-02-18 |
健泰科生物技术公司 |
抗体-药物偶联物和方法
|
US20150010550A1
(en)
|
2004-07-15 |
2015-01-08 |
Xencor, Inc. |
OPTIMIZED Fc VARIANTS
|
KR20070047327A
(ko)
*
|
2004-07-26 |
2007-05-04 |
비오겐 아이덱 엠에이 아이엔씨. |
항-cd154 항체
|
BR122018016031B8
(pt)
|
2004-08-04 |
2021-07-27 |
Applied Molecular Evolution Inc |
processo para produzir um anticorpo monoclonal variante com resposta de adcc realçada
|
WO2006023420A2
(en)
*
|
2004-08-16 |
2006-03-02 |
Medimmune, Inc. |
Integrin antagonists with enhanced antibody dependent cell-mediated cytotoxicity activity
|
BRPI0515230A
(pt)
*
|
2004-08-19 |
2008-07-15 |
Genentech Inc |
polipeptìdeos, anticorpos e ácidos nucléicos isolados, composições, vetor de expressão, células hospedeiras isoladas, método para a produção de um anticorpo, artigos manufaturados, métodos de tratamento e para o alìvio de disfunções, métodos de produção e de seleção de um polipeptìdeo, anticorpo de ligação cd20 humanizado, anticorpo anti-her2 isolado e usos de um anticorpo
|
US20060074225A1
(en)
*
|
2004-09-14 |
2006-04-06 |
Xencor, Inc. |
Monomeric immunoglobulin Fc domains
|
JP2008518023A
(ja)
|
2004-10-27 |
2008-05-29 |
メディミューン,インコーポレーテッド |
同族抗原に対する親和性を改変することによる抗体特異性の調節
|
US20060115485A1
(en)
*
|
2004-10-29 |
2006-06-01 |
Medimmune, Inc. |
Methods of preventing and treating RSV infections and related conditions
|
US7632497B2
(en)
|
2004-11-10 |
2009-12-15 |
Macrogenics, Inc. |
Engineering Fc Antibody regions to confer effector function
|
CN102746404B
(zh)
*
|
2004-11-12 |
2016-01-20 |
赞科股份有限公司 |
对FcRn的结合被改变的Fc变体
|
US20070135620A1
(en)
*
|
2004-11-12 |
2007-06-14 |
Xencor, Inc. |
Fc variants with altered binding to FcRn
|
US8802820B2
(en)
|
2004-11-12 |
2014-08-12 |
Xencor, Inc. |
Fc variants with altered binding to FcRn
|
US8546543B2
(en)
|
2004-11-12 |
2013-10-01 |
Xencor, Inc. |
Fc variants that extend antibody half-life
|
US8367805B2
(en)
|
2004-11-12 |
2013-02-05 |
Xencor, Inc. |
Fc variants with altered binding to FcRn
|
ES2323651T3
(es)
|
2005-01-05 |
2009-07-22 |
F-Star Biotechnologische Forschungs- Und Entwicklungsges.M.B.H. |
Dominios sinteticos de inmunoglobulina con propiedades de union elaborados por ingenieria en regiones de la molecula diferentes de las regiones que determinan la complementariedad.
|
EP1858925A2
(de)
*
|
2005-01-12 |
2007-11-28 |
Xencor, Inc. |
Antikörper und fc-fusionsproteine mit veränderter immunogenizität
|
US8956616B2
(en)
*
|
2005-01-24 |
2015-02-17 |
Board Of Regents, The University Of Texas System |
Constructs binding to phosphatidylserine and their use in disease treatment
|
JP5651285B2
(ja)
|
2005-02-15 |
2015-01-07 |
デューク ユニバーシティ |
抗cd19抗体および腫瘍学における使用
|
US8999943B2
(en)
|
2005-03-14 |
2015-04-07 |
Board Of Regents, The University Of Texas System |
Antigene oligomers inhibit transcription
|
WO2006106905A1
(ja)
|
2005-03-31 |
2006-10-12 |
Chugai Seiyaku Kabushiki Kaisha |
会合制御によるポリペプチド製造方法
|
US11254748B2
(en)
|
2005-04-15 |
2022-02-22 |
Macrogenics, Inc. |
Covalent diabodies and uses thereof
|
WO2012018687A1
(en)
|
2010-08-02 |
2012-02-09 |
Macrogenics, Inc. |
Covalent diabodies and uses thereof
|
US9963510B2
(en)
|
2005-04-15 |
2018-05-08 |
Macrogenics, Inc. |
Covalent diabodies and uses thereof
|
US9284375B2
(en)
|
2005-04-15 |
2016-03-15 |
Macrogenics, Inc. |
Covalent diabodies and uses thereof
|
AU2006236439B2
(en)
|
2005-04-15 |
2012-05-03 |
Macrogenics, Inc. |
Covalent diabodies and uses thereof
|
EP1874816A4
(de)
|
2005-04-26 |
2010-08-25 |
Medimmune Inc |
Modulation der antikörpereffektorfunktion mittels manipulation von verbindungsregionen
|
EP2221316A1
(de)
|
2005-05-05 |
2010-08-25 |
Duke University |
CD19-Antikörper-Therapie für Autoimmunerkrankungen
|
WO2006122079A1
(en)
|
2005-05-06 |
2006-11-16 |
Zymogenetics, Inc. |
Il-31 monoclonal antibodies and methods of use
|
US8163881B2
(en)
*
|
2005-05-31 |
2012-04-24 |
The Board Of Regents Of The University Of Texas System |
Immunoglobulin molecules with improved characteristics
|
CA2614181A1
(en)
*
|
2005-07-01 |
2007-01-11 |
Medimmune, Inc. |
An integrated approach for generating multidomain protein therapeutics
|
CA2618681C
(en)
|
2005-08-10 |
2015-10-27 |
Macrogenics, Inc. |
Identification and engineering of antibodies with variant fc regions and methods of using same
|
EP1931709B1
(de)
*
|
2005-10-03 |
2016-12-07 |
Xencor, Inc. |
Fc-varianten mit optimierten rezeptorbindungseigenschaften
|
AU2006302254B2
(en)
|
2005-10-06 |
2011-05-26 |
Xencor, Inc. |
Optimized anti-CD30 antibodies
|
KR20080073293A
(ko)
|
2005-10-14 |
2008-08-08 |
메디뮨 엘엘씨 |
항체 라이브러리의 세포 디스플레이
|
ES2577292T3
(es)
|
2005-11-07 |
2016-07-14 |
Genentech, Inc. |
Polipéptidos de unión con secuencias hipervariables de VH/VL diversificadas y consenso
|
EP2641970B1
(de)
|
2005-11-17 |
2014-12-24 |
Board of Regents, The University of Texas System |
Modulierung der Genexpression durch Oligomere, die auf chromosomale DNA ausgerichtet sind
|
JP5525729B2
(ja)
*
|
2005-11-28 |
2014-06-18 |
ゲンマブ エー/エス |
組換え一価抗体およびその作製方法
|
DK1963369T3
(da)
|
2005-11-28 |
2013-06-03 |
Zymogenetics Inc |
Il-21-antagonister
|
KR101434682B1
(ko)
|
2005-12-02 |
2014-08-27 |
제넨테크, 인크. |
결합 폴리펩티드 및 이들의 용도
|
WO2007092772A2
(en)
*
|
2006-02-03 |
2007-08-16 |
Medimmune, Inc. |
Protein formulations
|
WO2007103469A2
(en)
|
2006-03-06 |
2007-09-13 |
Aeres Biomedical Ltd. |
Humanized anti-cd22 antibodies and their use in treatment of oncology, transplantation and autoimmune disease
|
CN101479381B
(zh)
*
|
2006-03-31 |
2015-04-29 |
中外制药株式会社 |
调控抗体血液动力学的方法
|
EP3345616A1
(de)
|
2006-03-31 |
2018-07-11 |
Chugai Seiyaku Kabushiki Kaisha |
Antikörpermodifizierungsverfahren zur reinigung von bispezifischem antikörper
|
SG172656A1
(en)
|
2006-05-30 |
2011-07-28 |
Genentech Inc |
Antibodies and immunoconjugates and uses therefor
|
WO2008002933A2
(en)
|
2006-06-26 |
2008-01-03 |
Macrogenics, Inc. |
Combination of fcgammariib antibodies and cd20-specific antibodies and methods of use thereof
|
EP2505209A1
(de)
|
2006-06-26 |
2012-10-03 |
MacroGenics, Inc. |
Fcgamma-RIIB-spezifische Antikörper und Verfahren zu ihrer Anwendung
|
AT503889B1
(de)
|
2006-07-05 |
2011-12-15 |
Star Biotechnologische Forschungs Und Entwicklungsges M B H F |
Multivalente immunglobuline
|
AT503902B1
(de)
|
2006-07-05 |
2008-06-15 |
F Star Biotech Forsch & Entw |
Verfahren zur manipulation von immunglobulinen
|
AT503861B1
(de)
|
2006-07-05 |
2008-06-15 |
F Star Biotech Forsch & Entw |
Verfahren zur manipulation von t-zell-rezeptoren
|
CL2007002225A1
(es)
|
2006-08-03 |
2008-04-18 |
Astrazeneca Ab |
Agente de union especifico para un receptor del factor de crecimiento derivado de plaquetas (pdgfr-alfa); molecula de acido nucleico que lo codifica; vector y celula huesped que la comprenden; conjugado que comprende al agente; y uso del agente de un
|
CN103524619B
(zh)
|
2006-08-03 |
2016-10-05 |
阿斯利康(瑞典)有限公司 |
针对αVβ6的抗体及其应用
|
WO2008019290A2
(en)
|
2006-08-04 |
2008-02-14 |
Astrazeneca Ab |
Human antibodies to erbb 2
|
ME01786B
(me)
|
2006-08-14 |
2014-09-20 |
Xencor Inc |
Optimizovana antitela usmerena na cd19
|
SI2594586T1
(sl)
|
2006-09-01 |
2014-11-28 |
Zymogenetics, Inc. |
IL-31 monoklonska protitelesa in metode uporabe
|
ES2383710T3
(es)
|
2006-09-08 |
2012-06-25 |
Medimmune, Llc |
Anticuerpos anti-CD19 humanizados y su uso en el tratamiento de tumores, trasplantes y enfermedades autoinmunes
|
CA2660795C
(en)
|
2006-09-18 |
2014-11-18 |
Xencor, Inc. |
Optimized antibodies that target hm1.24
|
US20100143254A1
(en)
*
|
2006-10-16 |
2010-06-10 |
Medimmune, Llc |
Molecules with reduced half-lives, compositions and uses thereof
|
MX2009003938A
(es)
|
2006-10-27 |
2009-04-24 |
Genentech Inc |
Anticuerpos e inmunoconjugados y sus usos.
|
EP2687232A1
(de)
|
2006-12-06 |
2014-01-22 |
MedImmune, LLC |
Verfahren zur Behandlung von systemischem Lupus erythematodes
|
WO2008140603A2
(en)
|
2006-12-08 |
2008-11-20 |
Macrogenics, Inc. |
METHODS FOR THE TREATMENT OF DISEASE USING IMMUNOGLOBULINS HAVING FC REGIONS WITH ALTERED AFFINITIES FOR FCγR ACTIVATING AND FCγR INHIBITING
|
KR20140031996A
(ko)
|
2006-12-19 |
2014-03-13 |
제넨테크, 인크. |
조기 종양의 치료 및 아주반트 및 네오아주반트 요법을 위한 vegf-특이적 길항제
|
AU2008226905C1
(en)
|
2007-03-08 |
2014-11-06 |
Humanigen, Inc. |
EphA3 antibodies for the treatment of solid tumors
|
EP1980269A1
(de)
*
|
2007-04-13 |
2008-10-15 |
Katholieke Universiteit Leuven |
Prävention von Staphylokokken-Biofilmbildung
|
EP2703011A3
(de)
|
2007-05-07 |
2014-03-26 |
MedImmune, LLC |
Anti-Icos-Antikörper und ihre Verwendung bei der Behandlung von Krebs, Transplantationen und Autoimmunerkrankungen
|
EP3392273A1
(de)
|
2007-05-30 |
2018-10-24 |
Xencor, Inc. |
Verfahren und zusammensetzungen zur hemmung von cd32b-expressionszellen
|
EP1997830A1
(de)
|
2007-06-01 |
2008-12-03 |
AIMM Therapeutics B.V. |
RSV-spezifische Bindemoleküle und Mittel zu ihrer Herstellung
|
US7580304B2
(en)
*
|
2007-06-15 |
2009-08-25 |
United Memories, Inc. |
Multiple bus charge sharing
|
WO2009000006A1
(en)
|
2007-06-26 |
2008-12-31 |
F-Star Biotechnologische Forschungs- Und Entwicklungsges.M.B.H. |
Display of binding agents
|
WO2009006520A1
(en)
*
|
2007-07-03 |
2009-01-08 |
Medimmune, Llc |
Hinge domain engineering
|
EP2626371A1
(de)
|
2007-07-31 |
2013-08-14 |
MedImmune, LLC |
Multispezifische Epitopbindeproteine und ihre Verwendungen
|
PE20120259A1
(es)
|
2007-08-09 |
2012-04-04 |
Boehringer Ingelheim Int |
Anticuerpos anti-cd37
|
RU2010102859A
(ru)
*
|
2007-08-21 |
2011-09-27 |
Морфосис Аг (De) |
Улучшенные способы образования дисульфидных связей
|
CN106519025B
(zh)
|
2007-09-26 |
2021-04-23 |
中外制药株式会社 |
利用cdr的氨基酸取代来改变抗体等电点的方法
|
TWI464262B
(zh)
|
2007-09-26 |
2014-12-11 |
中外製藥股份有限公司 |
抗體固定區的變異
|
RU2530561C2
(ru)
|
2007-11-05 |
2014-10-10 |
Медиммун, Ллк |
Способы лечения склеродермии
|
AU2008324045B2
(en)
|
2007-11-09 |
2014-08-07 |
Affitech Research As |
Anti-VEGF antibody compositions and methods
|
CA2910933C
(en)
|
2007-12-07 |
2017-04-11 |
Zymogenetics, Inc. |
Anti-human il-21 monoclonal antibodies
|
HUE036548T2
(hu)
|
2007-12-07 |
2018-08-28 |
Zymogenetics Inc |
IL-31-re specifikus humanizált antitest molekulák
|
US8795667B2
(en)
|
2007-12-19 |
2014-08-05 |
Macrogenics, Inc. |
Compositions for the prevention and treatment of smallpox
|
EP2245064B1
(de)
|
2007-12-21 |
2014-07-23 |
Medimmune Limited |
BINDUNGSELEMENTE FÜR INTERLEUKIN-4-REZEPTOR ALPHA (IL-4Ralpha)
|
US8092804B2
(en)
|
2007-12-21 |
2012-01-10 |
Medimmune Limited |
Binding members for interleukin-4 receptor alpha (IL-4Rα)-173
|
ES2532461T3
(es)
*
|
2007-12-26 |
2015-03-27 |
Xencor, Inc. |
Variantes de FC con enlazamiento alterado a FCRN
|
BRPI0907046A2
(pt)
|
2008-01-18 |
2015-07-28 |
Medimmune Llc |
Anticorpo de cisteína engenheirada, ácido nucleico isolado, vetor, célula hospedeira, conjugado de anticorpo, composição farmacêutica, métodos de detecção de câncer, doenças ou distúrbios autoimunes, inflamatórios ou infecciosos em um indivíduo e de inibição de proliferação de uma célula alvo
|
EP2080770A1
(de)
*
|
2008-01-21 |
2009-07-22 |
MorphoSys AG |
Proteinöse Bindemoleküle mit Reinigungstags
|
AU2009212273B2
(en)
|
2008-02-08 |
2014-07-31 |
Astrazeneca Ab |
Anti-IFNAR1 antibodies with reduced Fc ligand affinity
|
EP2252631B1
(de)
|
2008-04-02 |
2016-04-13 |
MacroGenics, Inc. |
Bcr-komplex-spezifische antikörper und verfahren zu ihrer verwendung
|
AU2009231991B2
(en)
|
2008-04-02 |
2014-09-25 |
Macrogenics, Inc. |
HER2/neu-specific antibodies and methods of using same
|
UA121453C2
(uk)
|
2008-04-11 |
2020-06-10 |
Чугей Сейяку Кабусікі Кайся |
Спосіб одержання фармацевтичної композиції, яка містить антитіло
|
US8314213B2
(en)
*
|
2008-04-18 |
2012-11-20 |
Xencor, Inc. |
Human equivalent monoclonal antibodies engineered from nonhuman variable regions
|
EP2113255A1
(de)
|
2008-05-02 |
2009-11-04 |
f-star Biotechnologische Forschungs- und Entwicklungsges.m.b.H. |
Zytotoxisches Immunglobulin
|
WO2010009129A2
(en)
*
|
2008-07-15 |
2010-01-21 |
Genentech, Inc. |
Methods of treating autoimmune diseases using cd4 antibodies
|
AU2009294415B2
(en)
|
2008-09-19 |
2015-09-24 |
Medimmune Llc |
Antibodies directed to DLL4 and uses thereof
|
TWI440469B
(zh)
|
2008-09-26 |
2014-06-11 |
Chugai Pharmaceutical Co Ltd |
Improved antibody molecules
|
TWI572357B
(zh)
*
|
2008-10-14 |
2017-03-01 |
建南德克公司 |
免疫球蛋白變異體及其用途
|
US8298533B2
(en)
|
2008-11-07 |
2012-10-30 |
Medimmune Limited |
Antibodies to IL-1R1
|
CN102438652B
(zh)
|
2008-11-12 |
2014-08-13 |
米迪缪尼有限公司 |
抗体制剂
|
DK2752189T3
(en)
|
2008-11-22 |
2017-01-16 |
Hoffmann La Roche |
APPLICATION OF ANTI-VEGF ANTIBODY IN COMBINATION WITH CHEMOTHERY TO TREAT CANCER CANCER
|
WO2010068722A1
(en)
|
2008-12-12 |
2010-06-17 |
Medimmune, Llc |
Crystals and structure of a human igg fc variant with enhanced fcrn binding
|
EP2379595A2
(de)
|
2008-12-23 |
2011-10-26 |
AstraZeneca AB |
Gegen a5b1 gerichtete gezielt bindende mittel und anwendungen davon
|
AU2009334498A1
(en)
|
2008-12-31 |
2011-07-21 |
Biogen Idec Ma Inc. |
Anti-lymphotoxin antibodies
|
CN104119438A
(zh)
*
|
2009-01-29 |
2014-10-29 |
米迪缪尼有限公司 |
延长体内半衰期的人抗il-6抗体及其在治疗肿瘤、自身免疫性疾病和炎症性疾病中的应用
|
NZ594950A
(en)
|
2009-03-06 |
2013-06-28 |
Kalobios Pharmaceuticals Inc |
Treatment of leukemias and chronic myeloproliferative diseases with antibodies to epha3
|
EP3282021A1
(de)
|
2009-03-09 |
2018-02-14 |
Bioatla, LLC |
Mirac-proteine
|
JP5746134B2
(ja)
|
2009-03-16 |
2015-07-08 |
テバ・ファーマシューティカルズ・オーストラリア・ピーティワイ・リミテッド |
抗腫瘍活性を有するヒト化抗体
|
US9228017B2
(en)
|
2009-03-19 |
2016-01-05 |
Chugai Seiyaku Kabushiki Kaisha |
Antibody constant region variant
|
EP3674317A1
(de)
|
2009-03-19 |
2020-07-01 |
Chugai Seiyaku Kabushiki Kaisha |
Variante einer konstanten antikörperregion
|
EP2233500A1
(de)
|
2009-03-20 |
2010-09-29 |
LFB Biotechnologies |
Optimierte Fc Varianten
|
CN102378767B
(zh)
|
2009-03-25 |
2015-01-14 |
健泰科生物技术公司 |
抗-fgfr3抗体及其使用方法
|
MX2011011075A
(es)
|
2009-04-20 |
2011-11-04 |
Oxford Biotherapeutics Ltd |
Anticuerpos especificos para cadherina-17.
|
WO2010141329A1
(en)
*
|
2009-06-01 |
2010-12-09 |
Medimmune, Llc |
Molecules with extended half-lives and uses thereof
|
AU2010270979B2
(en)
|
2009-06-22 |
2015-04-23 |
Medimmune, Llc |
Engineered Fc regions for site-specific conjugation
|
WO2011020079A1
(en)
*
|
2009-08-13 |
2011-02-17 |
Calmune Corporation |
Antibodies against human respiratory syncytial virus (rsv) and methods of use
|
CA2769822C
(en)
|
2009-08-13 |
2019-02-19 |
The Johns Hopkins University |
Methods of modulating immune function
|
CN102573909A
(zh)
|
2009-08-15 |
2012-07-11 |
霍夫曼-拉罗奇有限公司 |
抗血管发生疗法用于治疗先前治疗过的乳腺癌
|
CA2772051C
(en)
|
2009-08-24 |
2020-08-18 |
Amunix Operating Inc. |
Coagulation factor ix compositions and methods of making and using same
|
WO2011028952A1
(en)
|
2009-09-02 |
2011-03-10 |
Xencor, Inc. |
Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens
|
WO2011031870A1
(en)
|
2009-09-09 |
2011-03-17 |
Centrose, Llc |
Extracellular targeted drug conjugates
|
WO2011035205A2
(en)
|
2009-09-18 |
2011-03-24 |
Calmune Corporation |
Antibodies against candida, collections thereof and methods of use
|
WO2011037158A1
(ja)
|
2009-09-24 |
2011-03-31 |
中外製薬株式会社 |
抗体定常領域改変体
|
US8568726B2
(en)
|
2009-10-06 |
2013-10-29 |
Medimmune Limited |
RSV specific binding molecule
|
PL2486141T3
(pl)
|
2009-10-07 |
2018-07-31 |
Macrogenics, Inc. |
Polipeptydy zawierające regiony fc i mające w wyniku zmian w zakresie fukozylacji ulepszoną funkcję efektorową, i sposoby zastosowania tych polipeptydów
|
WO2011047083A1
(en)
|
2009-10-13 |
2011-04-21 |
Oxford Biotherapeutics Ltd. |
Antibodies against epha10
|
WO2011053465A1
(en)
|
2009-10-14 |
2011-05-05 |
Kalobios Pharmaceuticals, Inc. |
Antibodies to epha3
|
TW201121566A
(en)
|
2009-10-22 |
2011-07-01 |
Genentech Inc |
Anti-hepsin antibodies and methods using same
|
IL297588A
(en)
|
2009-11-02 |
2022-12-01 |
Univ Washington |
Therapeutic nuclease preparations and methods
|
EP2496600A1
(de)
|
2009-11-04 |
2012-09-12 |
Fabrus LLC |
Verfahren zur optimierung von antikörpern auf der basis von affinitätsreifung
|
JP5822841B2
(ja)
|
2009-11-05 |
2015-11-24 |
テバ・ファーマシューティカルズ・オーストラリア・ピーティワイ・リミテッド |
変異型のkrasまたはbraf遺伝子を含むがんの治療
|
JP6173690B2
(ja)
|
2009-11-05 |
2017-08-02 |
ジェネンテック, インコーポレイテッド |
異種ポリペプチドの分泌のための方法及び組成物
|
US8881354B2
(en)
|
2009-11-16 |
2014-11-11 |
Jtekt Corporation |
Tool radius adjusting system for boring holder, tool radius adjusting method in machine tool, and machine tool
|
PT2504364T
(pt)
|
2009-11-24 |
2017-11-14 |
Medimmune Ltd |
Agentes de ligação direcionados contra b7-h1
|
US9023996B2
(en)
|
2009-12-23 |
2015-05-05 |
Synimmune Gmbh |
Anti-FLT3 antibodies
|
TWI535445B
(zh)
|
2010-01-12 |
2016-06-01 |
安可美德藥物股份有限公司 |
Wnt拮抗劑及治療和篩選方法
|
CN102958534B
(zh)
|
2010-01-13 |
2014-11-05 |
昂考梅德药品有限公司 |
Notch1结合剂及其使用方法
|
US8362210B2
(en)
|
2010-01-19 |
2013-01-29 |
Xencor, Inc. |
Antibody variants with enhanced complement activity
|
WO2011089211A1
(en)
|
2010-01-22 |
2011-07-28 |
Synimmune Gmbh |
Anti-cd133 antibodies and methods of using the same
|
CA2789629A1
(en)
|
2010-02-10 |
2011-08-18 |
Immunogen, Inc. |
Cd20 antibodies and uses thereof
|
WO2011102845A1
(en)
*
|
2010-02-18 |
2011-08-25 |
Transtech Pharma, Inc. |
Rage fusion protein compositions and methods of use
|
KR101839161B1
(ko)
|
2010-02-23 |
2018-03-16 |
제넨테크, 인크. |
난소암의 치료를 위한 항혈관신생 요법
|
CN103805202B
(zh)
|
2010-02-25 |
2018-05-18 |
旭化成株式会社 |
氧化铜用蚀刻液以及使用其的蚀刻方法
|
WO2011108714A1
(ja)
|
2010-03-04 |
2011-09-09 |
中外製薬株式会社 |
抗体定常領域改変体
|
US9150656B2
(en)
|
2010-03-04 |
2015-10-06 |
Macrogenics, Inc. |
Antibodies reactive with B7-H3, immunologically active fragments thereof and uses thereof
|
US8802091B2
(en)
|
2010-03-04 |
2014-08-12 |
Macrogenics, Inc. |
Antibodies reactive with B7-H3 and uses thereof
|
CN106432474A
(zh)
|
2010-03-12 |
2017-02-22 |
艾伯维生物医疗股份有限公司 |
Ctla4蛋白和其用途
|
TWI667346B
(zh)
|
2010-03-30 |
2019-08-01 |
中外製藥股份有限公司 |
促進抗原消失之具有經修飾的FcRn親和力之抗體
|
ES2552954T3
(es)
|
2010-04-30 |
2015-12-03 |
Alexion Pharmaceuticals, Inc. |
Anticuerpos anti-C5a y métodos para el uso de los anticuerpos
|
CN103080130B
(zh)
|
2010-05-27 |
2016-08-17 |
默沙东公司 |
制备具有改进特性的抗体的方法
|
WO2011153243A2
(en)
|
2010-06-02 |
2011-12-08 |
Genentech, Inc. |
Anti-angiogenesis therapy for treating gastric cancer
|
EP2577310B1
(de)
|
2010-06-03 |
2018-11-14 |
F.Hoffmann-La Roche Ag |
Immun-pet-bildgebung von antikörpern und immunkonjugaten sowie ihre verwendungen
|
AU2011261185A1
(en)
|
2010-06-03 |
2013-01-10 |
Pharmacyclics, Inc. |
The use of inhibitors of Bruton's tyrosine kinase (Btk)
|
USRE49339E1
(en)
|
2010-06-22 |
2022-12-20 |
The Regents Of The University Of Colorado, A Body Corporate |
Antibodies to the C3D fragment of complement component 3
|
WO2012006633A1
(en)
|
2010-07-09 |
2012-01-12 |
Biogen Idec Hemophilia Inc. |
Chimeric clotting factors
|
NZ603488A
(en)
|
2010-07-09 |
2015-02-27 |
Crucell Holland Bv |
Anti-human respiratory syncytial virus (rsv) antibodies and methods of use
|
NZ604415A
(en)
|
2010-07-20 |
2014-10-31 |
Cephalon Australia Pty Ltd |
Anti-il-23 heterodimer specific antibodies
|
WO2012012750A1
(en)
|
2010-07-23 |
2012-01-26 |
Trustees Of Boston University |
ANTI-DEsupR INHIBITORS AS THERAPEUTICS FOR INHIBITION OF PATHOLOGICAL ANGIOGENESIS AND TUMOR CELL INVASIVENESS AND FOR MOLECULAR IMAGING AND TARGETED DELIVERY
|
HUE063115T2
(hu)
|
2010-07-29 |
2023-12-28 |
Buzzard Pharmaceuticals AB |
Kiméra I-es típusú IL-1 receptor antagonisták
|
WO2012019061A2
(en)
|
2010-08-05 |
2012-02-09 |
Stem Centrx, Inc. |
Novel effectors and methods of use
|
WO2012020096A1
(en)
|
2010-08-13 |
2012-02-16 |
Medimmune Limited |
Monomeric polypeptides comprising variant fc regions and methods of use
|
WO2012022734A2
(en)
|
2010-08-16 |
2012-02-23 |
Medimmune Limited |
Anti-icam-1 antibodies and methods of use
|
AU2011293127B2
(en)
|
2010-08-27 |
2016-05-12 |
Abbvie Stemcentrx Llc |
Notum protein modulators and methods of use
|
SG10201506959SA
(en)
|
2010-09-03 |
2015-10-29 |
Stemcentrx Inc |
Novel modulators and methods of use
|
EP3828205A1
(de)
|
2010-10-01 |
2021-06-02 |
Oxford BioTherapeutics Ltd |
Anti-ror1-antikörper
|
UA112062C2
(uk)
|
2010-10-04 |
2016-07-25 |
Бьорінгер Інгельхайм Інтернаціональ Гмбх |
Cd33-зв'язувальний агент
|
SG189322A1
(en)
|
2010-10-13 |
2013-05-31 |
Janssen Biotech Inc |
Human oncostatin m antibodies and methods of use
|
WO2012058768A1
(en)
|
2010-11-05 |
2012-05-10 |
Zymeworks Inc. |
Stable heterodimeric antibody design with mutations in the fc domain
|
CN105859889B
(zh)
|
2010-11-17 |
2020-01-07 |
中外制药株式会社 |
具有代替凝血因子viii的功能的功能的多特异性抗原结合分子
|
DK2643352T3
(en)
|
2010-11-23 |
2018-07-30 |
Glaxo Group Ltd |
Antigen Binding Proteins for Oncostatin M (OSM)
|
KR20130121886A
(ko)
|
2010-11-24 |
2013-11-06 |
글락소 그룹 리미티드 |
Hgf를 표적으로 하는 다중특이적 항원 결합 단백질
|
SG10201509790YA
(en)
|
2010-11-30 |
2015-12-30 |
Chugai Pharmaceutical Co Ltd |
Antigen-Binding Molecule Capable Of Binding To Plurality Of Antigen Molecules Repeatedly
|
TWI685503B
(zh)
|
2010-11-30 |
2020-02-21 |
中外製藥股份有限公司 |
細胞傷害誘導治療劑
|
RU2592672C9
(ru)
|
2010-12-08 |
2016-11-27 |
СтемСентРкс, Инк. |
Новые модуляторы и способы их применения
|
CN103429261A
(zh)
|
2010-12-22 |
2013-12-04 |
塞法隆澳大利亚股份有限公司 |
半寿期改进的修饰抗体
|
JOP20210044A1
(ar)
|
2010-12-30 |
2017-06-16 |
Takeda Pharmaceuticals Co |
الأجسام المضادة لـ cd38
|
WO2012103240A2
(en)
|
2011-01-25 |
2012-08-02 |
Eleven Biotherapeutics, Inc. |
Receptor binding agents
|
WO2012106634A1
(en)
|
2011-02-03 |
2012-08-09 |
Alexion Pharmaceuticals, Inc. |
Use of an anti-cd200 antibody for prolonging the survival of allografts
|
US10689447B2
(en)
|
2011-02-04 |
2020-06-23 |
Genentech, Inc. |
Fc variants and methods for their production
|
JP2014508748A
(ja)
|
2011-02-08 |
2014-04-10 |
メディミューン,エルエルシー |
黄色ブドウ球菌(Staphylococcusaureus)α毒素に特異的に結合する抗体及び使用方法
|
SA112330278B1
(ar)
|
2011-02-18 |
2015-10-09 |
ستيم سينتركس، انك. |
مواد ضابطة جديدة وطرق للاستخدام
|
CN103492565B
(zh)
|
2011-02-25 |
2021-01-29 |
中外制药株式会社 |
FcγRIIb特异性Fc抗体
|
SG10201602394QA
(en)
|
2011-03-29 |
2016-05-30 |
Roche Glycart Ag |
Antibody FC Variants
|
CN103502273A
(zh)
|
2011-04-20 |
2014-01-08 |
罗氏格黎卡特股份公司 |
用于pH依赖性通过血脑屏障的方法和构建体
|
EP2699256B1
(de)
|
2011-04-21 |
2017-09-27 |
The Regents of the University of Colorado, a body corporate |
Zusammensetzungen und verfahren zur behandlung von neuromyelitis optica
|
CN107964539B
(zh)
|
2011-04-29 |
2022-06-28 |
华盛顿大学 |
治疗性核酸酶组合物和方法
|
NZ618016A
(en)
|
2011-05-21 |
2015-05-29 |
Macrogenics Inc |
Deimmunized serum-binding domains and their use for extending serum half-life
|
DK2714738T3
(en)
|
2011-05-24 |
2019-01-28 |
Zyngenia Inc |
MULTIVALENT AND MONOVALENT MULTISPECIFIC COMPLEXES AND THEIR APPLICATIONS
|
KR20140028013A
(ko)
|
2011-05-25 |
2014-03-07 |
머크 샤프 앤드 돔 코포레이션 |
개선된 특성을 갖는 Fc-함유 폴리펩티드를 제조하는 방법
|
WO2012170742A2
(en)
|
2011-06-07 |
2012-12-13 |
University Of Hawaii |
Treatment and prevention of cancer with hmgb1 antagonists
|
WO2012170740A2
(en)
|
2011-06-07 |
2012-12-13 |
University Of Hawaii |
Biomarker of asbestos exposure and mesothelioma
|
JP6058645B2
(ja)
|
2011-06-10 |
2017-01-11 |
メディミューン,エルエルシー |
抗シュードモナス属(Pseudomonas)Psl結合分子およびその使用
|
PT2717898T
(pt)
|
2011-06-10 |
2019-05-20 |
Bioverativ Therapeutics Inc |
Compostos pró-coagulantes e processos para a sua utilização
|
DK2718326T3
(da)
|
2011-06-13 |
2020-10-26 |
Csl Ltd |
Antistoffer mod g-csfr og anvendelser deraf
|
JP6216921B2
(ja)
|
2011-06-24 |
2017-11-01 |
ザ リージェンツ オブ ザ ユニバーシティ オブ コロラド,ア ボディー コーポレイトTHE REGENTS OF THE UNIVERSITY OF COLORADO,a body corporate |
アルファ−1抗トリプシン融合分子のための組成物、方法および使用
|
US10400029B2
(en)
|
2011-06-28 |
2019-09-03 |
Inhibrx, Lp |
Serpin fusion polypeptides and methods of use thereof
|
KR20140068861A
(ko)
*
|
2011-06-28 |
2014-06-09 |
인히브릭스 엘엘씨 |
Wap 도메인 융합 폴리펩티드 및 이의 이용 방법
|
MY160826A
(en)
|
2011-06-28 |
2017-03-31 |
Berlin-Chemie Ag |
Antibodies to bone marrow stromal antigen 1
|
CN110551223A
(zh)
*
|
2011-06-28 |
2019-12-10 |
英伊布里克斯有限合伙公司 |
丝氨酸蛋白酶抑制蛋白融合多肽及其使用方法
|
UA117901C2
(uk)
|
2011-07-06 |
2018-10-25 |
Ґенмаб Б.В. |
Спосіб посилення ефекторної функції вихідного поліпептиду, його варіанти та їх застосування
|
CN106167526A
(zh)
|
2011-07-15 |
2016-11-30 |
昂考梅德药品有限公司 |
Rspo结合剂和其应用
|
WO2013012733A1
(en)
|
2011-07-15 |
2013-01-24 |
Biogen Idec Ma Inc. |
Heterodimeric fc regions, binding molecules comprising same, and methods relating thereto
|
GB201112429D0
(en)
|
2011-07-19 |
2011-08-31 |
Glaxo Group Ltd |
Antigen-binding proteins with increased FcRn binding
|
EP2548892A1
(de)
|
2011-07-22 |
2013-01-23 |
CSL Behring GmbH |
Inhibitorische Antikörper gegen Factor XII/XIIa und ihre Verwendungen
|
JP6253578B2
(ja)
|
2011-07-22 |
2017-12-27 |
ツェー・エス・エル・ベーリング・ゲー・エム・ベー・ハー |
阻害性抗第xii/xiia因子モノクローナル抗体及びそれらの使用
|
US20130022551A1
(en)
|
2011-07-22 |
2013-01-24 |
Trustees Of Boston University |
DEspR ANTAGONISTS AND AGONISTS AS THERAPEUTICS
|
CA2842099A1
(en)
|
2011-07-27 |
2013-01-31 |
Glaxo Group Limited |
Antigen binding constructs
|
RU2014107743A
(ru)
|
2011-07-29 |
2015-09-10 |
Илэвэн Байотерапьютикс, Инк. |
Очищенные белки
|
US20130058947A1
(en)
|
2011-09-02 |
2013-03-07 |
Stem Centrx, Inc |
Novel Modulators and Methods of Use
|
UY34317A
(es)
|
2011-09-12 |
2013-02-28 |
Genzyme Corp |
Anticuerpo antireceptor de célula T (alfa)/ß
|
US20130108641A1
(en)
|
2011-09-14 |
2013-05-02 |
Sanofi |
Anti-gitr antibodies
|
PL3485903T3
(pl)
|
2011-09-23 |
2023-06-12 |
Mereo Biopharma 5, Inc. |
Środki wiążące VEGF/DLL4 i ich zastosowania
|
BR122020013379B1
(pt)
|
2011-09-30 |
2023-01-03 |
Teva Pharmaceuticals Australia Pty Ltd |
Anticorpos contra tl1a e seus usos
|
KR20200096692A
(ko)
|
2011-09-30 |
2020-08-12 |
추가이 세이야쿠 가부시키가이샤 |
항원의 소실을 촉진시키는 항원 결합 분자
|
CN110627902A
(zh)
|
2011-09-30 |
2019-12-31 |
中外制药株式会社 |
诱导针对靶抗原的免疫应答的抗原结合分子
|
EP2762493B1
(de)
|
2011-09-30 |
2021-06-09 |
Chugai Seiyaku Kabushiki Kaisha |
Antigenbindende moleküle zur förderung der zersetzung von antigenen mit mehreren biologischen aktivitäten
|
TW201326209A
(zh)
|
2011-09-30 |
2013-07-01 |
Chugai Pharmaceutical Co Ltd |
具有促進抗原清除之FcRn結合域的治療性抗原結合分子
|
EP3617313A1
(de)
|
2011-10-05 |
2020-03-04 |
Chugai Seiyaku Kabushiki Kaisha |
Antigenbindendes molekül zur herstellung eines abstands zwischen einem plasma und einem antigen mit einer saccharidkettenrezeptor-bindenden domäne
|
CN116063509A
(zh)
|
2011-10-11 |
2023-05-05 |
维埃拉生物股份有限公司 |
Cd40l-特异性tn3-衍生的支架及其使用方法
|
US20140302021A1
(en)
|
2011-10-25 |
2014-10-09 |
Onclave Therapeutics Limited |
Antibody formulations and methods
|
BR112014009925B1
(pt)
|
2011-10-28 |
2022-09-20 |
Teva Pharmaceuticals Australia Pty Ltd |
Construtores de polipeptídeos e seus usos
|
EP2773373B1
(de)
|
2011-11-01 |
2018-08-22 |
Bionomics, Inc. |
Verfahren zur blockierung eines krebsstammzellenwachstums
|
AU2012332593B2
(en)
|
2011-11-01 |
2016-11-17 |
Bionomics, Inc. |
Anti-GPR49 antibodies
|
CN104053671A
(zh)
|
2011-11-01 |
2014-09-17 |
生态学有限公司 |
治疗癌症的抗体和方法
|
WO2013067057A1
(en)
|
2011-11-01 |
2013-05-10 |
Bionomics, Inc. |
Anti-gpr49 antibodies
|
CN109897103A
(zh)
|
2011-11-04 |
2019-06-18 |
酵活有限公司 |
在Fc结构域中具有突变的稳定异源二聚的抗体设计
|
CA2854806A1
(en)
|
2011-11-07 |
2013-05-16 |
Medimmune, Llc |
Multispecific and multivalent binding proteins and uses thereof
|
AU2012336028A1
(en)
|
2011-11-07 |
2014-06-26 |
Medimmune, Llc |
Combination therapies using anti- Pseudomonas Psl and PcrV binding molecules
|
WO2013074598A1
(en)
*
|
2011-11-18 |
2013-05-23 |
Merck Sharp & Dohme Corp. |
Fc CONTAINING POLYPEPTIDES HAVING INCREASED ANTI-INFLAMMATORY PROPERTIES AND INCREASED FcRN BINDING
|
DK2797957T3
(da)
|
2011-11-23 |
2019-09-23 |
Medimmune Llc |
Bindingsmolekyler specifikke for her3 og anvendelser deraf
|
KR20210074395A
(ko)
|
2011-11-30 |
2021-06-21 |
추가이 세이야쿠 가부시키가이샤 |
면역 복합체를 형성하는 세포내로의 운반체(캐리어)를 포함하는 의약
|
CN107353342B
(zh)
|
2011-12-05 |
2021-08-10 |
X 博迪生物科学公司 |
PDGF受体β结合多肽
|
ES2816078T3
(es)
|
2011-12-20 |
2021-03-31 |
Medimmune Llc |
Polipéptidos modificados para armazones de anticuerpo biespecífico
|
ES2751386T3
(es)
*
|
2011-12-21 |
2020-03-31 |
Amgen Inc |
Polipéptidos Fc variantes con unión potenciada al receptor de Fc neonatal
|
US9988439B2
(en)
|
2011-12-23 |
2018-06-05 |
Nicholas B. Lydon |
Immunoglobulins and variants directed against pathogenic microbes
|
WO2013096948A1
(en)
|
2011-12-23 |
2013-06-27 |
Lydon Nicholas B |
Immunoglobulins and variants directed against pathogenic microbes
|
EP3539982A3
(de)
|
2011-12-23 |
2020-01-15 |
Pfizer Inc |
Konstante regionen gentechnisch hergestellter antikörper für stellenspezifische konjugation sowie verfahren und verwendungen dafür
|
KR102041412B1
(ko)
*
|
2011-12-30 |
2019-11-11 |
한미사이언스 주식회사 |
면역글로불린 Fc 단편 유도체
|
KR102348985B1
(ko)
|
2012-01-10 |
2022-01-12 |
더 리젠츠 오브 더 유니버시티 오브 콜로라도, 어 바디 코포레이트 |
알파-1 안티트립신 융합 분자용 조성물, 방법 및 용도
|
ES2753124T3
(es)
|
2012-01-12 |
2020-04-07 |
Bioverativ Therapeutics Inc |
Polipéptidos quiméricos de factor VIII y usos de los mismos
|
EP2623110A1
(de)
|
2012-01-31 |
2013-08-07 |
CSL Behring GmbH |
Faktor-XII-Hemmer zur Behandlung neurologischer Entzündungserkrankungen
|
CN113527469A
(zh)
*
|
2012-02-09 |
2021-10-22 |
中外制药株式会社 |
抗体的Fc区变异体
|
CA2864904C
(en)
|
2012-02-15 |
2023-04-25 |
Amunix Operating Inc. |
Factor viii compositions and methods of making and using same
|
BR112014019901A8
(pt)
|
2012-02-15 |
2018-01-02 |
Biogen Idec Inc |
Proteínas de fator viii recombinante
|
PL2817338T3
(pl)
|
2012-02-24 |
2017-12-29 |
Abbvie Stemcentrx Llc |
Modulatory DLL3 i sposoby zastosowania
|
AU2013223087B2
(en)
|
2012-02-24 |
2018-02-22 |
Chugai Seiyaku Kabushiki Kaisha |
Antigen-binding molecule for promoting disappearance of antigen via FcgammaRIIb
|
KR102166083B1
(ko)
|
2012-03-28 |
2020-10-16 |
사노피 |
브라디키닌 b1 수용체 리간드에 대한 항체
|
WO2013155346A1
(en)
|
2012-04-11 |
2013-10-17 |
The Regents Of The University Of California |
Diagnostic tools for response to 6-thiopurine therapy
|
US9212227B2
(en)
*
|
2012-04-30 |
2015-12-15 |
Janssen Biotech, Inc. |
ST2L antibody antagonists for the treatment of ST2L-mediated inflammatory pulmonary conditions
|
EP2844289B1
(de)
*
|
2012-04-30 |
2019-07-17 |
MedImmune, LLC |
Moleküle mit verminderter effektorfunktion und verlängerter halbwertzeit sowie zusammensetzungen damit und verwendungen davon
|
WO2013169657A1
(en)
|
2012-05-07 |
2013-11-14 |
Sanofi |
Methods for preventing biofilm formation
|
EP2847230B1
(de)
|
2012-05-10 |
2020-08-12 |
Zymeworks Inc. |
Heteromultimerkonstrukte aus schweren immunoglobulinketten mit mutationen in der fc-domäne
|
GB201208370D0
(en)
*
|
2012-05-14 |
2012-06-27 |
Ucb Pharma Sa |
Antibodies
|
WO2013175276A1
(en)
|
2012-05-23 |
2013-11-28 |
Argen-X B.V |
Il-6 binding molecules
|
ES2856272T3
(es)
|
2012-05-30 |
2021-09-27 |
Chugai Pharmaceutical Co Ltd |
Molécula de unión a antígenos para eliminar antígenos agregados
|
KR20220092644A
(ko)
|
2012-05-30 |
2022-07-01 |
추가이 세이야쿠 가부시키가이샤 |
표적 조직 특이적 항원 결합 분자
|
CA2875980A1
(en)
|
2012-06-06 |
2013-12-12 |
Oncomed Pharmaceuticals, Inc. |
Binding agents that modulate the hippo pathway and uses thereof
|
US10202595B2
(en)
|
2012-06-08 |
2019-02-12 |
Bioverativ Therapeutics Inc. |
Chimeric clotting factors
|
AU2013270682A1
(en)
|
2012-06-08 |
2014-12-11 |
Biogen Ma Inc. |
Procoagulant compounds
|
WO2014004586A1
(en)
|
2012-06-25 |
2014-01-03 |
Zymeworks Inc. |
Process and methods for efficient manufacturing of highly pure asymmetric antibodies in mammalian cells
|
WO2014008480A2
(en)
|
2012-07-06 |
2014-01-09 |
Biogen Idec Ma Inc. |
Cell line expressing single chain factor viii polypeptides and uses thereof
|
EP3632462A1
(de)
|
2012-07-06 |
2020-04-08 |
Genmab B.V. |
Dimerprotein mit dreifacher mutation
|
US11180572B2
(en)
|
2012-07-06 |
2021-11-23 |
Genmab B.V. |
Dimeric protein with triple mutations
|
CN104661674A
(zh)
|
2012-07-11 |
2015-05-27 |
阿穆尼克斯运营公司 |
具有xten和血管性血友病因子蛋白的因子viii复合物、及其用途
|
MA37794B1
(fr)
|
2012-07-13 |
2017-07-31 |
Roche Glycart Ag |
Anticorps bispécifiques anti-vegf/anti-ang-2 et leur utilisation dans le cadre du traitement de pathologies vasculaires oculaires
|
CN104704129A
(zh)
|
2012-07-24 |
2015-06-10 |
药品循环公司 |
与对布鲁顿酪氨酸激酶(btk)抑制剂的抗性相关的突变
|
RU2681730C2
(ru)
|
2012-07-25 |
2019-03-12 |
Селлдекс Терапьютикс Инк. |
Антитела против kit и их применения
|
WO2014029752A1
(en)
|
2012-08-22 |
2014-02-27 |
Glaxo Group Limited |
Anti lrp6 antibodies
|
WO2014030728A1
(ja)
|
2012-08-24 |
2014-02-27 |
中外製薬株式会社 |
FcγRIIb特異的Fc領域改変体
|
JP6774164B2
(ja)
|
2012-08-24 |
2020-10-21 |
中外製薬株式会社 |
マウスFcγRII特異的Fc抗体
|
US9790268B2
(en)
|
2012-09-12 |
2017-10-17 |
Genzyme Corporation |
Fc containing polypeptides with altered glycosylation and reduced effector function
|
KR102185151B1
(ko)
|
2012-09-12 |
2020-12-01 |
젠자임 코포레이션 |
변경된 당화 및 감소된 효과기 기능을 갖는 fc 함유 폴리펩티드
|
US9914785B2
(en)
|
2012-11-28 |
2018-03-13 |
Zymeworks Inc. |
Engineered immunoglobulin heavy chain-light chain pairs and uses thereof
|
MX2015006973A
(es)
|
2012-12-04 |
2015-09-28 |
Oncomed Pharm Inc |
Inmunoterapia con agentes de enlace.
|
WO2014100483A1
(en)
|
2012-12-19 |
2014-06-26 |
Amplimmune, Inc. |
Anti-human b7-h4 antibodies and their uses
|
RU2691428C2
(ru)
|
2012-12-21 |
2019-06-13 |
МЕДИММЬЮН, ЭлЭлСи |
Антитела к h7cr
|
WO2014108198A1
(en)
|
2013-01-10 |
2014-07-17 |
Genmab B.V. |
Human igg1 fc region variants and uses thereof
|
BR112015017619A2
(pt)
|
2013-01-24 |
2017-11-21 |
Glaxosmithkline Ip Dev Ltd |
formulação líquida, uso de uma formulação, e, kit
|
JP6475639B2
(ja)
|
2013-01-25 |
2019-02-27 |
シャイアー ヒューマン ジェネティック セラピーズ インコーポレイテッド |
デュシェンヌ筋ジストロフィーの治療におけるフォリスタチン
|
AU2014213009B2
(en)
|
2013-02-01 |
2019-01-03 |
Kira Biotech Pty Limited |
Anti-CD83 antibodies and use thereof
|
CN105073195A
(zh)
|
2013-02-04 |
2015-11-18 |
昂科梅德制药有限公司 |
使用Wnt途径抑制剂进行治疗的方法及对该治疗的监测
|
WO2014121325A1
(en)
|
2013-02-07 |
2014-08-14 |
Csl Limited |
Il-11r binding proteins and uses thereof
|
DK3889173T3
(da)
|
2013-02-15 |
2023-10-09 |
Bioverativ Therapeutics Inc |
Optimeret faktor viii-gen
|
RU2019109456A
(ru)
|
2013-02-22 |
2019-04-10 |
ЭББВИ СТЕМСЕНТРКС ЭлЭлСи |
Новые конъюгаты антител и их применения
|
US9487587B2
(en)
|
2013-03-05 |
2016-11-08 |
Macrogenics, Inc. |
Bispecific molecules that are immunoreactive with immune effector cells of a companion animal that express an activating receptor and cells that express B7-H3 and uses thereof
|
JP6636334B2
(ja)
|
2013-03-08 |
2020-01-29 |
ツェー・エス・エル・ベーリング・ゲー・エム・ベー・ハー |
遠隔虚血再灌流傷害の治療および予防
|
KR20220103204A
(ko)
|
2013-03-11 |
2022-07-21 |
젠자임 코포레이션 |
과글리코실화된 결합 폴리펩티드
|
DK2968468T3
(en)
|
2013-03-13 |
2021-07-26 |
Buzzard Pharmaceuticals AB |
Chimeric cytokine formulations for ocular delivery
|
US20140271641A1
(en)
|
2013-03-14 |
2014-09-18 |
University Of Guelph |
Thrombospondin-1 polypeptides and methods of using same
|
LT2968520T
(lt)
|
2013-03-14 |
2021-09-27 |
Macrogenics, Inc. |
Bispecifinės molekulės, kurios yra imunoreaktyvios imuninių efektorių ląstelėms, kurios ekspresuoja aktyvuojantį receptorių
|
EP2970484B2
(de)
|
2013-03-15 |
2022-09-21 |
Amgen Inc. |
Heterodimere bispezifische antikörper
|
RU2015144033A
(ru)
|
2013-03-15 |
2017-04-26 |
Эббви Байотекнолоджи Лтд. |
Антитела против cd25 и их применения
|
EP2970488A2
(de)
|
2013-03-15 |
2016-01-20 |
AbbVie Biotechnology Ltd |
Anti-cd25-antikörper und deren verwendungen
|
AR095527A1
(es)
|
2013-03-15 |
2015-10-21 |
Biogen Idec Inc |
Formulaciones de polipéptido fc-factor ix
|
US20140302037A1
(en)
|
2013-03-15 |
2014-10-09 |
Amgen Inc. |
BISPECIFIC-Fc MOLECULES
|
US9260527B2
(en)
|
2013-03-15 |
2016-02-16 |
Sdix, Llc |
Anti-human CXCR4 antibodies and methods of making same
|
US9587235B2
(en)
|
2013-03-15 |
2017-03-07 |
Atyr Pharma, Inc. |
Histidyl-tRNA synthetase-Fc conjugates
|
US20140377253A1
(en)
|
2013-03-15 |
2014-12-25 |
Abbvie Biotherapeutics Inc. |
Fc variants
|
EA201890895A1
(ru)
|
2013-03-15 |
2019-02-28 |
Зинджения, Инк. |
Мультивалентные и моновалентные мультиспецифические комплексы и их применение
|
JP6224739B2
(ja)
|
2013-03-15 |
2017-11-01 |
グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドGlaxosmithkline Intellectual Property Development Limited |
抗lag−3結合タンパク質
|
BR112015024587B1
(pt)
|
2013-04-02 |
2022-11-29 |
Chugai Seiyaku Kabushiki Kaisha |
Variante de região fc de igg1 humana, polipeptídeo compreendendo a mesma, seu método de produção e composição farmacêutica
|
US11117975B2
(en)
|
2013-04-29 |
2021-09-14 |
Teva Pharmaceuticals Australia Pty Ltd |
Anti-CD38 antibodies and fusions to attenuated interferon alpha-2B
|
BR112015027313A2
(pt)
|
2013-04-29 |
2017-09-26 |
Teva Pharmaceuticals Australia Pty Ltd |
anticorpos anti-cd38 e fusões ao interferon alfa-2b atenuado
|
KR102293064B1
(ko)
|
2013-05-20 |
2021-08-23 |
제넨테크, 인크. |
항-트랜스페린 수용체 항체 및 사용 방법
|
US10513555B2
(en)
|
2013-07-04 |
2019-12-24 |
Prothena Biosciences Limited |
Antibody formulations and methods
|
EP3875106A1
(de)
|
2013-08-08 |
2021-09-08 |
Bioverativ Therapeutics Inc. |
Reinigung von chimären fviii-molekülen
|
US11384149B2
(en)
|
2013-08-09 |
2022-07-12 |
Macrogenics, Inc. |
Bi-specific monovalent Fc diabodies that are capable of binding CD32B and CD79b and uses thereof
|
UA116479C2
(uk)
|
2013-08-09 |
2018-03-26 |
Макродженікс, Інк. |
БІСПЕЦИФІЧНЕ МОНОВАЛЕНТНЕ Fc-ДІАТІЛО, ЯКЕ ОДНОЧАСНО ЗВ'ЯЗУЄ CD32B I CD79b, ТА ЙОГО ЗАСТОСУВАННЯ
|
SG10201710013RA
(en)
|
2013-08-13 |
2018-01-30 |
Sanofi Sa |
Antibodies to plasminogen activator inhibitor-1 (pai-1) and uses thereof
|
TW201722994A
(zh)
|
2013-08-13 |
2017-07-01 |
賽諾菲公司 |
胞漿素原活化素抑制劑-1(pai-1)之抗體及其用途
|
US10548953B2
(en)
|
2013-08-14 |
2020-02-04 |
Bioverativ Therapeutics Inc. |
Factor VIII-XTEN fusions and uses thereof
|
EP2840091A1
(de)
|
2013-08-23 |
2015-02-25 |
MacroGenics, Inc. |
Bispezifische Diabodies, die gpA33 und CD3 binden können und Anwendungen dieser
|
EP2839842A1
(de)
|
2013-08-23 |
2015-02-25 |
MacroGenics, Inc. |
Bispezifische monovalente Diabodies mit Fähigkeit zur Bindung von CD123 und CD3 und Verwendungen davon
|
WO2015031541A1
(en)
|
2013-08-28 |
2015-03-05 |
Stem Centrx, Inc. |
Novel sez6 modulators and methods of use
|
EP3892294A1
(de)
|
2013-08-28 |
2021-10-13 |
AbbVie Stemcentrx LLC |
Konjugationsverfahren stellenspezifischer antikörper und zusammensetzungen
|
WO2015035044A2
(en)
|
2013-09-04 |
2015-03-12 |
Abbvie Biotherapeutics Inc. |
Fc VARIANTS WITH IMPROVED ANTIBODY-DEPENDENT CELL-MEDIATED CYTOTOXICITY
|
EP3702373B9
(de)
|
2013-09-13 |
2022-11-23 |
BeiGene Switzerland GmbH |
Anti-pd1-antikörper sowie verwendung davon in therapeutika und diagnostika
|
US20160257748A1
(en)
|
2013-09-25 |
2016-09-08 |
Amgen Inc. |
V-c-fc-v-c antibody
|
HUE057005T2
(hu)
|
2013-09-25 |
2022-04-28 |
Bioverativ Therapeutics Inc |
Oszlopon történõ vírusinaktiváló eljárások
|
PT3050896T
(pt)
|
2013-09-27 |
2021-08-24 |
Chugai Pharmaceutical Co Ltd |
Processo para a produção de heteromultímeros de polipéptidos
|
WO2015050959A1
(en)
|
2013-10-01 |
2015-04-09 |
Yale University |
Anti-kit antibodies and methods of use thereof
|
KR102357635B1
(ko)
|
2013-10-02 |
2022-01-28 |
메디뮨 엘엘씨 |
중화 항-인플루엔자 a 항체 및 이의 용도
|
BR112016007402B1
(pt)
|
2013-10-11 |
2023-03-28 |
Oxford Biotherapeutics Ltd |
Anticorpo isolado, ou uma porção de ligação de antígeno deste, composição farmacêutica o compreendendo e seu uso, bem como ácido nucléico, vetor de expressão e método de produção de um anticorpo ou uma porção de ligação de antígeno deste
|
EP3063275B1
(de)
|
2013-10-31 |
2019-09-25 |
Resolve Therapeutics, LLC |
Therapeutische nuklease-albumin-fusionen und verfahren
|
KR20160070191A
(ko)
|
2013-11-06 |
2016-06-17 |
스템센트알엑스 인코포레이티드 |
신규한 항-클라우딘 항체 및 사용 방법
|
WO2015070014A1
(en)
|
2013-11-08 |
2015-05-14 |
Biogen Idec Ma Inc. |
Procoagulant fusion compound
|
GB201320066D0
(en)
|
2013-11-13 |
2013-12-25 |
Ucb Pharma Sa |
Biological products
|
ES2909014T3
(es)
*
|
2013-11-26 |
2022-05-04 |
Brigham & Womens Hospital Inc |
Composiciones y métodos para modular una respuesta inmunitaria
|
CA2931975A1
(en)
|
2013-12-02 |
2015-06-11 |
Oncomed Pharmaceuticals, Inc. |
Identification of predictive biomarkers associated with wnt pathway inhibitors
|
TWI702316B
(zh)
|
2013-12-04 |
2020-08-21 |
日商中外製藥股份有限公司 |
因應化合物濃度使抗原結合能力變化的抗原結合分子及其資料庫
|
NZ720769A
(en)
|
2013-12-09 |
2022-10-28 |
Allakos Inc |
Anti-siglec-8 antibodies and methods of use thereof
|
EP2883883A1
(de)
|
2013-12-16 |
2015-06-17 |
Cardio3 Biosciences S.A. |
Therapeutische Ziele und Mittel zur Behandlung von ischämiebedingten Reperfusionsschäden
|
US8986691B1
(en)
|
2014-07-15 |
2015-03-24 |
Kymab Limited |
Method of treating atopic dermatitis or asthma using antibody to IL4RA
|
US8980273B1
(en)
|
2014-07-15 |
2015-03-17 |
Kymab Limited |
Method of treating atopic dermatitis or asthma using antibody to IL4RA
|
SG10202009832XA
(en)
|
2013-12-24 |
2020-11-27 |
Argenx Bvba |
Fcrn antagonists and methods of use
|
CN106456718A
(zh)
|
2014-01-10 |
2017-02-22 |
比奥根Ma公司 |
因子viii嵌合蛋白及其用途
|
US10675352B2
(en)
|
2014-02-14 |
2020-06-09 |
Centrose, Llc |
Extracellular targeted drug conjugates
|
US10183996B2
(en)
|
2014-02-28 |
2019-01-22 |
Allakos Inc. |
Methods and compositions for treating Siglec-8 associated diseases
|
NZ711451A
(en)
|
2014-03-07 |
2016-05-27 |
Alexion Pharma Inc |
Anti-c5 antibodies having improved pharmacokinetics
|
AU2015229035B2
(en)
|
2014-03-14 |
2021-08-05 |
Genentech, Inc. |
Methods and compositions for secretion of heterologous polypeptides
|
US9738702B2
(en)
*
|
2014-03-14 |
2017-08-22 |
Janssen Biotech, Inc. |
Antibodies with improved half-life in ferrets
|
FI3129067T3
(fi)
|
2014-03-19 |
2023-04-04 |
Genzyme Corp |
Kohdennusosien kohtaspesifinen glykomodifiointi
|
EP3119910A4
(de)
|
2014-03-20 |
2018-02-21 |
Pharmacyclics LLC |
Phospholipase c gamma 2 und resistenzassoziierte mutationen
|
AU2015231155B2
(en)
|
2014-03-21 |
2020-11-12 |
X-Body, Inc. |
Bi-specific antigen-binding polypeptides
|
US9546214B2
(en)
|
2014-04-04 |
2017-01-17 |
Bionomics, Inc. |
Humanized antibodies that bind LGR5
|
MA50678A
(fr)
|
2014-04-08 |
2020-08-05 |
Boston Pharmaceuticals Inc |
Molécules de liaison spécifiques de l'il-21 et leurs utilisations
|
UA119352C2
(uk)
|
2014-05-01 |
2019-06-10 |
Тева Фармасьютикалз Острейліа Пті Лтд |
Комбінація леналідоміду або помалідоміду і конструкції анти-cd38 антитіло-атенуйований інтерферон альфа-2b та спосіб лікування суб'єкта, який має cd38-експресуючу пухлину
|
WO2015175874A2
(en)
|
2014-05-16 |
2015-11-19 |
Medimmune, Llc |
Molecules with altered neonate fc receptor binding having enhanced therapeutic and diagnostic properties
|
SG10201912986PA
(en)
|
2014-05-28 |
2020-02-27 |
Agenus Inc |
Anti-gitr antibodies and methods of use thereof
|
US20170211876A1
(en)
*
|
2014-06-12 |
2017-07-27 |
Hoffmann-La Roche Inc. |
Method for selecting antibodies with modified fcrn interaction
|
WO2015196070A1
(en)
|
2014-06-20 |
2015-12-23 |
Genentech, Inc. |
Chagasin-based scaffold compositions, methods, and uses
|
EP3160478A4
(de)
|
2014-06-30 |
2018-05-16 |
Bioverativ Therapeutics Inc. |
Optimiertes faktor-ix-gen
|
CN110156892B
(zh)
|
2014-07-03 |
2023-05-16 |
百济神州有限公司 |
抗pd-l1抗体及其作为治疗剂及诊断剂的用途
|
CN113563462A
(zh)
|
2014-07-15 |
2021-10-29 |
免疫医疗有限责任公司 |
中和抗乙型流感抗体及其用途
|
EP3171892B1
(de)
|
2014-07-22 |
2021-11-24 |
Apollomics Inc. |
Anti-pd-1-antikörper
|
SG11201700687TA
(en)
|
2014-08-05 |
2017-02-27 |
Cb Therapeutics Inc |
Anti-pd-l1 antibodies
|
CA2958018A1
(en)
|
2014-08-11 |
2016-02-18 |
University Of Massachusetts |
Anti-ospa antibodies and methods of use
|
AP2017009776A0
(en)
|
2014-09-03 |
2017-02-28 |
Boehringer Ingelheim Int |
Compound targeting il-23a and tnf-alpha and uses thereof
|
TW201617368A
(zh)
|
2014-09-05 |
2016-05-16 |
史坦森特瑞斯公司 |
新穎抗mfi2抗體及使用方法
|
CA2960128A1
(en)
|
2014-09-25 |
2016-03-31 |
Amgen Inc |
Protease-activatable bispecific proteins
|
CN107001440A
(zh)
|
2014-09-26 |
2017-08-01 |
拜耳制药股份公司 |
稳定化的肾上腺髓质素衍生物及其用途
|
MA40764A
(fr)
|
2014-09-26 |
2017-08-01 |
Chugai Pharmaceutical Co Ltd |
Agent thérapeutique induisant une cytotoxicité
|
MX2017004076A
(es)
|
2014-09-29 |
2017-07-04 |
Univ Duke |
Moleculas biespecificas que comprenden un brazo orientado a la envoltura vih-1.
|
RU2021125449A
(ru)
|
2014-10-01 |
2021-09-16 |
Медиммьюн Лимитед |
Антитела к тикагрелору и способы применения
|
EP3799887A1
(de)
|
2014-10-09 |
2021-04-07 |
Genzyme Corporation |
Durch glycoengineering hergestellte antikörperarzneimittelkonjugate
|
ES2753391T3
(es)
|
2014-10-14 |
2020-04-08 |
Halozyme Inc |
Composiciones de adenosina desaminasa 2 (ADA2), variantes de la misma y métodos de uso de las mismas
|
WO2016061617A1
(en)
|
2014-10-23 |
2016-04-28 |
Dendrocyte Biotech Pty Ltd |
Cd83 binding proteins and uses thereof
|
WO2016065409A1
(en)
|
2014-10-29 |
2016-05-06 |
Teva Pharmaceuticals Australia Pty Ltd |
INTERFERON α2B VARIANTS
|
US20160130324A1
(en)
*
|
2014-10-31 |
2016-05-12 |
Shire Human Genetic Therapies, Inc. |
C1 Inhibitor Fusion Proteins and Uses Thereof
|
KR20170080675A
(ko)
|
2014-11-05 |
2017-07-10 |
제넨테크, 인크. |
항-fgfr2/3 항체 및 이의 이용 방법
|
MX2017005150A
(es)
*
|
2014-11-06 |
2017-08-08 |
Hoffmann La Roche |
Variantes de region fc con propiedades modificadas de union a receptor neonatal fc (fcrn) y proteina a.
|
HUE054339T2
(hu)
|
2014-11-10 |
2021-08-30 |
Medimmune Ltd |
CD73-ra specifikus kötõmolekulák és alkalmazásaik
|
GB2538120A
(en)
|
2014-11-11 |
2016-11-09 |
Medimmune Ltd |
Therapeutic combinations comprising anti-CD73 antibodies and uses thereof
|
WO2016081643A1
(en)
|
2014-11-19 |
2016-05-26 |
Genentech, Inc. |
Anti-transferrin receptor antibodies and methods of use
|
WO2016081640A1
(en)
|
2014-11-19 |
2016-05-26 |
Genentech, Inc. |
Anti-transferrin receptor / anti-bace1 multispecific antibodies and methods of use
|
EP3789399A1
(de)
|
2014-11-21 |
2021-03-10 |
Bristol-Myers Squibb Company |
Antikörper mit modifizierten schweren konstanten regionen
|
BR112017010110A2
(pt)
|
2014-11-21 |
2018-01-30 |
Bristol-Myers Squibb Company |
anticorpos contra cd73 e usos do mesmo
|
US9382321B2
(en)
|
2014-11-26 |
2016-07-05 |
Adventis Health System/Sunbelt, Inc. |
Effector-deficient anti-CD32A antibodies
|
BR112017011234A2
(pt)
|
2014-12-10 |
2018-03-27 |
Genentech Inc |
anticorpos contra receptor da barreira hematoencefálica e métodos de uso
|
MA41294A
(fr)
|
2014-12-19 |
2017-11-08 |
Chugai Pharmaceutical Co Ltd |
Anticorps anti-myostatine, polypeptides contenant des variants de régions fc, et procédés d'utilisation
|
EP3233921B1
(de)
|
2014-12-19 |
2021-09-29 |
Chugai Seiyaku Kabushiki Kaisha |
Anti-c5-antikörper und verfahren zur verwendung
|
WO2016094962A1
(en)
|
2014-12-19 |
2016-06-23 |
Monash University |
Il-21 antibodies
|
CA2972048C
(en)
|
2014-12-22 |
2023-03-07 |
The Rockefeller University |
Anti-mertk agonistic antibodies and uses thereof
|
SG10202006538TA
(en)
|
2014-12-23 |
2020-08-28 |
Bristol Myers Squibb Co |
Antibodies to tigit
|
SG11201705721WA
(en)
|
2015-01-14 |
2017-08-30 |
Brigham & Womens Hospital Inc |
Treatment of cancer with anti-lap monoclonal antibodies
|
US20180215801A1
(en)
|
2015-01-29 |
2018-08-02 |
Board Of Trustees Of Michigan State University |
Cryptic polypeptides and uses thereof
|
KR102605798B1
(ko)
|
2015-02-05 |
2023-11-23 |
추가이 세이야쿠 가부시키가이샤 |
이온 농도 의존적 항원 결합 도메인을 포함하는 항체, Fc 영역 개변체, IL-8에 결합하는 항체, 및 그들의 사용
|
WO2016131893A1
(en)
|
2015-02-18 |
2016-08-25 |
Medimmune Limited |
Incretin fusion polypeptides
|
TWI759261B
(zh)
|
2015-02-27 |
2022-04-01 |
日商中外製藥股份有限公司 |
Il-6受體抗體用於製備醫藥組成物的用途
|
JP2018509413A
(ja)
|
2015-03-09 |
2018-04-05 |
アルゲン−エックス ビーブイビーエー |
FcRnアンタゴニストを用いてFc含有剤の血清レベルを低下させる方法
|
CN108064236B
(zh)
|
2015-03-31 |
2021-12-10 |
免疫医疗有限公司 |
新颖的il33形式、il33的突变形式、抗体、测定及其使用方法
|
FR3034420A1
(fr)
|
2015-03-31 |
2016-10-07 |
Lab Francais Du Fractionnement |
Anticorps monoclonaux anti-cd303
|
US11142587B2
(en)
|
2015-04-01 |
2021-10-12 |
Chugai Seiyaku Kabushiki Kaisha |
Method for producing polypeptide hetero-oligomer
|
EP3303396B1
(de)
|
2015-05-29 |
2022-11-23 |
Bristol-Myers Squibb Company |
Antikörper gegen ox40 und verwendungen davon
|
KR101978765B1
(ko)
|
2015-06-04 |
2019-05-15 |
오스페달레 산 라파엘 에스.알.엘. |
Igfbp3/tmem219 축 및 당뇨병의 저해제
|
BR112017025995A2
(pt)
|
2015-06-04 |
2018-08-14 |
Ospedale San Raffaele S.R.L. |
inibidor de igfbp3, composição farmacêutica para uso no tratamento e/ou prevenção de um distúrbio intestinal, método para o diagnóstico de um distúrbio intestinal em um indivíduo e kit para o diagnóstico de um distúrbio intestinal
|
AU2016270858B2
(en)
|
2015-06-05 |
2022-04-28 |
Ac Immune Sa |
Anti-Tau antibodies and methods of use
|
TWI773646B
(zh)
|
2015-06-08 |
2022-08-11 |
美商宏觀基因股份有限公司 |
結合lag-3的分子和其使用方法
|
AU2016278239B9
(en)
|
2015-06-17 |
2022-08-11 |
Allakos Inc. |
Methods and compositions for treating fibrotic diseases
|
CA2990015A1
(en)
|
2015-06-29 |
2017-01-05 |
The Rockefeller University |
Antibodies to cd40 with enhanced agonist activity
|
IL256665B2
(en)
|
2015-07-23 |
2023-10-01 |
Boehringer Ingelheim Int |
IL-23A Targeting Compound and B-Cell Activating Factor Nucleic Acids Encoding Them and Use of Products Containing Them
|
GEP20227438B
(en)
|
2015-07-30 |
2022-11-10 |
Macrogenics Inc |
Pd-1-binding molecules and methods of use thereof
|
EP3329018B1
(de)
|
2015-07-31 |
2021-03-31 |
Medimmune Limited |
Il-6 antagonisten zur verwendung in der behandlung von hepcidin-vermittelten krankheiten
|
UA126016C2
(uk)
|
2015-08-03 |
2022-08-03 |
Біовератів Терапеутікс Інк. |
Злитий білок фактора іх
|
CN114605548A
(zh)
|
2015-09-01 |
2022-06-10 |
艾吉纳斯公司 |
抗-pd-1抗体及其使用方法
|
JP7074341B2
(ja)
|
2015-09-02 |
2022-05-24 |
イムテップ エス.アー.エス. |
抗lag-3抗体
|
TWI799366B
(zh)
|
2015-09-15 |
2023-04-21 |
美商建南德克公司 |
胱胺酸結骨架平臺
|
US20190022092A1
(en)
|
2015-09-15 |
2019-01-24 |
Acerta Pharma B.V. |
Therapeutic Combinations of a BTK Inhibitor and a GITR Binding Molecule, a 4-1BB Agonist, or an OX40 Agonist
|
TWI703158B
(zh)
|
2015-09-18 |
2020-09-01 |
美商希佛隆公司 |
特異性結合tl1a之抗體
|
AU2016326609B2
(en)
|
2015-09-23 |
2023-03-09 |
Mereo Biopharma 5, Inc. |
Methods and compositions for treatment of cancer
|
SG11201801984TA
(en)
|
2015-10-01 |
2018-04-27 |
Heat Biologics Inc |
Compositions and methods for adjoining type i and type ii extracellular domains as heterologous chimeric proteins
|
MA45429A
(fr)
|
2015-10-08 |
2019-05-01 |
Macrogenics Inc |
Polythérapie pour le traitement du cancer
|
CA3001676C
(en)
|
2015-10-12 |
2022-12-06 |
Aprogen Kic Inc. |
Anti-cd43 antibody and use thereof for cancer treatment
|
US10604577B2
(en)
|
2015-10-22 |
2020-03-31 |
Allakos Inc. |
Methods and compositions for treating systemic mastocytosis
|
EP3374398B1
(de)
|
2015-11-10 |
2020-03-18 |
MedImmune, LLC |
Für asct2 spezifische bindemoleküle und verwendungen davon
|
US10188660B2
(en)
|
2015-11-30 |
2019-01-29 |
Abbvie Inc. |
Anti-huLRRC15 antibody drug conjugates and methods for their use
|
JP2019501124A
(ja)
|
2015-11-30 |
2019-01-17 |
アッヴィ・インコーポレイテッド |
抗huLRRC15抗体薬物コンジュゲート及びその使用方法
|
EP3383430A4
(de)
|
2015-12-02 |
2019-12-18 |
Agenus Inc. |
Antikörper und verfahren zur verwendung davon
|
AR107781A1
(es)
|
2015-12-14 |
2018-06-06 |
Macrogenics Inc |
Moléculas biespecíficas que tienen inmunorreactividad con pd-1 y ctla-4, y métodos de uso de las mismas
|
JP7141336B2
(ja)
|
2015-12-25 |
2022-09-22 |
中外製薬株式会社 |
抗ミオスタチン抗体および使用方法
|
CN108368166B
(zh)
|
2015-12-28 |
2023-03-28 |
中外制药株式会社 |
提高含fc区多肽纯化效率的方法
|
EP3398968A4
(de)
|
2015-12-31 |
2019-08-07 |
Jiangsu Hengrui Medicine Co., Ltd. |
Pcsk9-antikörper, antigenbindendes fragment davon und medizinische anwendung davon
|
WO2017118307A1
(zh)
|
2016-01-05 |
2017-07-13 |
江苏恒瑞医药股份有限公司 |
Pcsk9抗体、其抗原结合片段及其医药用途
|
CN116218863A
(zh)
|
2016-02-01 |
2023-06-06 |
比奥贝拉蒂治疗公司 |
优化的因子viii基因
|
US20170233472A1
(en)
|
2016-02-17 |
2017-08-17 |
Macrogenics, Inc. |
ROR1-Binding Molecules, and Methods of Use Thereof
|
WO2017152085A1
(en)
|
2016-03-04 |
2017-09-08 |
Bristol-Myers Squibb Company |
Combination therapy with anti-cd73 antibodies
|
KR20180137487A
(ko)
|
2016-03-04 |
2018-12-27 |
샤이어 휴먼 지네틱 테라피즈 인크. |
재조합 폴리스타틴-fc 융합 단백질 및 듀시엔형 근이영양증 치료에서의 용도
|
AU2016394956B2
(en)
|
2016-03-04 |
2024-02-08 |
The Rockefeller University |
Antibodies to CD40 with enhanced agonist activity
|
AU2017233658B2
(en)
|
2016-03-14 |
2023-09-21 |
Chugai Seiyaku Kabushiki Kaisha |
Cell injury inducing therapeutic drug for use in cancer therapy
|
US11066464B2
(en)
|
2016-03-21 |
2021-07-20 |
Kymab Limited |
Anti-malarial antibodies that bind circumsporozoite protein
|
CA3018081A1
(en)
|
2016-03-22 |
2017-09-28 |
Bionomics Limited |
Administration of an anti-lgr5 monoclonal antibody
|
MA45473A
(fr)
|
2016-04-04 |
2019-02-13 |
Shire Human Genetic Therapies |
Inhibiteur de c1 estérase conjugué et ses utilisations
|
CN116790614A
(zh)
|
2016-04-04 |
2023-09-22 |
比奥贝拉蒂美国公司 |
抗补体因子bb抗体以及其用途
|
EP3442574A4
(de)
|
2016-04-15 |
2019-12-11 |
MacroGenics, Inc. |
Neuartige b7-h3-bindende moleküle, antikörper-wirkstoff-konjugate davon und verfahren zur verwendung davon
|
CA3021098A1
(en)
|
2016-04-21 |
2017-10-26 |
Abbvie Stemcentrx Llc |
Novel anti-bmpr1b antibodies and methods of use
|
CA3024508A1
(en)
|
2016-05-27 |
2017-11-30 |
Agenus Inc. |
Anti-tim-3 antibodies and methods of use thereof
|
CA3026880A1
(en)
|
2016-06-08 |
2017-12-14 |
Paul Foster |
Treatment of igg4-related diseases with anti-cd19 antibodies crossbinding to cd32b
|
DK3478713T3
(da)
|
2016-06-30 |
2022-06-20 |
Prothena Biosciences Ltd |
Sammensætninger til behandling af amyloidose
|
CN109790526A
(zh)
|
2016-07-01 |
2019-05-21 |
分解治疗有限责任公司 |
优化的二核酸酶融合体和方法
|
CN109475536B
(zh)
|
2016-07-05 |
2022-05-27 |
百济神州有限公司 |
用于治疗癌症的PD-l拮抗剂和RAF抑制剂的组合
|
CN109689685A
(zh)
|
2016-07-08 |
2019-04-26 |
斯塔滕生物技术有限公司 |
抗apoc3抗体及其使用方法
|
JP7316930B2
(ja)
|
2016-07-15 |
2023-07-28 |
武田薬品工業株式会社 |
形質芽細胞及び形質細胞枯渇療法に対する応答を評価するための方法及び材料
|
WO2018014067A1
(en)
|
2016-07-19 |
2018-01-25 |
Teva Pharmaceuticals Australia Pty Ltd |
Anti-cd47 combination therapy
|
BR112019001989A2
(pt)
|
2016-08-02 |
2019-08-20 |
Visterra Inc |
polipeptídeos projetados e usos dos mesmos
|
US11053308B2
(en)
|
2016-08-05 |
2021-07-06 |
Chugai Seiyaku Kabushiki Kaisha |
Method for treating IL-8-related diseases
|
CN109689090B
(zh)
|
2016-08-05 |
2023-12-26 |
免疫医疗有限责任公司 |
抗o2抗体及其用途
|
US20210332112A1
(en)
*
|
2016-08-15 |
2021-10-28 |
Board Of Regents, The University Of Texas System |
Stabilized pertussis antibodies with extended half-life
|
US10538579B2
(en)
|
2016-08-15 |
2020-01-21 |
Board Of Regents, The University Of Texas System |
Bispecific pertussis antibodies
|
DK3500299T3
(da)
|
2016-08-19 |
2024-01-29 |
Beigene Switzerland Gmbh |
Kombination af zanubrutinib med et anti-CD20- eller et anti-PD-1-antistof til anvendelse i behandling af cancer
|
JP2019534858A
(ja)
|
2016-09-09 |
2019-12-05 |
ジェネンテック, インコーポレイテッド |
Frizzledの選択的ペプチド阻害剤
|
WO2018053032A1
(en)
|
2016-09-13 |
2018-03-22 |
Humanigen, Inc. |
Epha3 antibodies for the treatment of pulmonary fibrosis
|
SG10201607778XA
(en)
|
2016-09-16 |
2018-04-27 |
Chugai Pharmaceutical Co Ltd |
Anti-Dengue Virus Antibodies, Polypeptides Containing Variant Fc Regions, And Methods Of Use
|
AU2017343621B2
(en)
|
2016-10-11 |
2021-12-02 |
Agenus Inc. |
Anti-LAG-3 antibodies and methods of use thereof
|
JP7160484B2
(ja)
|
2016-10-19 |
2022-10-25 |
メディミューン,エルエルシー |
抗o1抗体およびその使用
|
TW202300515A
(zh)
|
2016-10-20 |
2023-01-01 |
法商賽諾菲公司 |
抗chikv抗體及其用途
|
CN110035771B
(zh)
|
2016-10-21 |
2024-03-08 |
阿迪马布有限责任公司 |
抗呼吸道合胞病毒抗体及其产生和使用方法
|
JP7265984B2
(ja)
|
2016-10-21 |
2023-04-27 |
アディマブ, エルエルシー |
抗呼吸器合胞体ウイルス抗体、及び、それらの生成及び使用の方法
|
AU2017345786A1
(en)
|
2016-10-21 |
2019-05-23 |
Adimab, Llc |
Anti-respiratory syncytial virus antibodies, and methods of their generation and use
|
TWI788307B
(zh)
|
2016-10-31 |
2023-01-01 |
美商艾歐凡斯生物治療公司 |
用於擴增腫瘤浸潤性淋巴細胞之工程化人造抗原呈現細胞
|
WO2018089628A1
(en)
|
2016-11-09 |
2018-05-17 |
Agenus Inc. |
Anti-ox40 antibodies, anti-gitr antibodies, and methods of use thereof
|
AU2017368328A1
(en)
|
2016-12-02 |
2019-07-18 |
Bioverativ Therapeutics Inc. |
Methods of inducing immune tolerance to clotting factors
|
AU2017366709A1
(en)
|
2016-12-02 |
2019-07-18 |
Bioverativ Therapeutics Inc. |
Methods of treating hemophilic arthropathy using chimeric clotting factors
|
WO2018104893A1
(en)
|
2016-12-06 |
2018-06-14 |
Glaxosmithkline Intellectual Property Development Limited |
Alpha4-beta7 antibodies with incrased fcrn binding and/or half-life
|
JP7106538B2
(ja)
|
2016-12-07 |
2022-07-26 |
アジェナス インコーポレイテッド |
抗体およびその使用方法
|
EP3551660B1
(de)
|
2016-12-07 |
2023-09-13 |
Agenus Inc. |
Anti-ctla-4-antikörper und verfahren zur verwendung davon
|
SG10201911351SA
(en)
|
2016-12-07 |
2020-02-27 |
Genentech Inc |
Anti-tau antibodies and methods of use
|
JP2020511937A
(ja)
|
2016-12-07 |
2020-04-23 |
ジェネンテック, インコーポレイテッド |
抗tau抗体及び使用方法
|
PE20191497A1
(es)
|
2016-12-21 |
2019-10-21 |
Cephalon Inc |
Anticuerpos que se unen especificamente a il-15 humana y usos de estos
|
CN110267685B
(zh)
|
2016-12-23 |
2023-06-20 |
伊缪诺金公司 |
靶向adam9的免疫缀合物及其使用方法
|
JP7128819B2
(ja)
|
2016-12-23 |
2022-08-31 |
マクロジェニクス,インコーポレーテッド |
Adam9結合分子、およびその使用方法
|
TW201825515A
(zh)
|
2017-01-04 |
2018-07-16 |
美商伊繆諾金公司 |
Met抗體以及其免疫結合物及用途
|
KR20190104048A
(ko)
|
2017-01-06 |
2019-09-05 |
이오반스 바이오테라퓨틱스, 인크. |
종양 괴사 인자 수용체 슈퍼패밀리 (tnfrsf) 효능제를 사용한 종양 침윤 림프구 (til)의 확장 및 til과 tnfrsf 효능제의 치료 조합물
|
EP3565586A1
(de)
|
2017-01-06 |
2019-11-13 |
Iovance Biotherapeutics, Inc. |
Erweiterung von tumorinfiltrierenden lymphozyten mit kaliumkanalagonisten und therapeutische verwendungen davon
|
JP7082424B2
(ja)
|
2017-01-25 |
2022-06-08 |
モレキュラー テンプレーツ,インク. |
脱免疫化された志賀毒素aサブユニットエフェクター及びcd8+t細胞エピトープを含む細胞標的化分子
|
EP3574004A1
(de)
|
2017-01-25 |
2019-12-04 |
Medimmune, LLC |
Relaxin-fusionspolypeptide und verwendungen davon
|
TWI774726B
(zh)
|
2017-01-25 |
2022-08-21 |
英屬開曼群島商百濟神州有限公司 |
(S)-7-(1-(丁-2-炔醯基)哌啶-4-基)-2-(4-苯氧基苯基)-4,5,6,7-四氫吡唑并[1,5-a]嘧啶-3-甲醯胺的晶型、及其製備和用途
|
AU2018214554C1
(en)
|
2017-02-01 |
2022-12-15 |
Novo Nordisk A/S |
Treatment of diuretic resistance
|
JP7304288B2
(ja)
|
2017-02-17 |
2023-07-06 |
サノフイ |
ジストログリカンおよびラミニン2に対する特異性を有する多特異性結合性分子
|
US10626169B2
(en)
|
2017-02-17 |
2020-04-21 |
Sanofi |
Multispecific binding molecules having specificity to dystroglycan and laminin-2
|
WO2018152326A1
(en)
|
2017-02-17 |
2018-08-23 |
Denali Therapeutics Inc. |
Engineered transferrin receptor binding polypeptides
|
MX2019009967A
(es)
|
2017-02-24 |
2019-12-02 |
Macrogenics Inc |
Moleculas de union biespecificas que son capaces de unirse a cd137 y a antigenos tumorales, y usos de las mismas.
|
AU2018224852A1
(en)
|
2017-02-27 |
2019-07-11 |
Shattuck Labs, Inc. |
VSIG8-based chimeric proteins
|
GB201703876D0
(en)
|
2017-03-10 |
2017-04-26 |
Berlin-Chemie Ag |
Pharmaceutical combinations
|
KR20190129925A
(ko)
|
2017-03-16 |
2019-11-20 |
메디뮨 리미티드 |
항-par2 항체 및 그의 용도
|
UY37651A
(es)
|
2017-03-31 |
2018-10-31 |
Swedish Orphan Biovitrum Ab Publ |
Polipéptido de unión al il-1r-i
|
TWI788340B
(zh)
|
2017-04-07 |
2023-01-01 |
美商必治妥美雅史谷比公司 |
抗icos促效劑抗體及其用途
|
AU2018253176B2
(en)
|
2017-04-13 |
2023-02-02 |
Agenus Inc. |
Anti-CD137 antibodies and methods of use thereof
|
CA3058290A1
(en)
|
2017-04-18 |
2018-10-25 |
Universite Libre De Bruxelles |
Biomarkers and targets for proliferative diseases
|
US11767520B2
(en)
|
2017-04-20 |
2023-09-26 |
Atyr Pharma, Inc. |
Compositions and methods for treating lung inflammation
|
JP2020517242A
(ja)
|
2017-04-21 |
2020-06-18 |
スターテン・バイオテクノロジー・ベー・フェー |
抗ApoC3抗体およびその使用方法
|
HUE062927T2
(hu)
|
2017-05-01 |
2023-12-28 |
Agenus Inc |
Anti-TIGIT ellenanyagok és alkalmazási eljárásaik
|
WO2018203545A1
(ja)
|
2017-05-02 |
2018-11-08 |
国立研究開発法人国立精神・神経医療研究センター |
Il-6及び好中球の関連する疾患の治療効果の予測及び判定方法
|
CA3062415A1
(en)
|
2017-05-05 |
2018-11-08 |
Christopher Robert Bebbington |
Methods and compositions for treating allergic ocular diseases
|
TW201904578A
(zh)
|
2017-05-10 |
2019-02-01 |
美商艾歐凡斯生物治療公司 |
源自液體腫瘤之腫瘤浸潤性淋巴細胞的擴增和該經擴增腫瘤浸潤性淋巴細胞之治療用途
|
AU2018266893A1
(en)
|
2017-05-12 |
2019-12-05 |
Takeda Pharmaceutical Company Limited |
Recombinant follistatin-Fc fusion proteins and use in treating Duchenne muscular dystrophy
|
JOP20190271A1
(ar)
|
2017-05-24 |
2019-11-21 |
Novartis Ag |
بروتينات مطعّمة بسيتوكين- الجسم المضاد وطرق الاستخدام للاضطرابات المتعلقة بالمناعة
|
EP4098662A1
(de)
|
2017-05-25 |
2022-12-07 |
Bristol-Myers Squibb Company |
Antikörper mit modifizierten schweren konstanten regionen
|
GB201709970D0
(en)
|
2017-06-22 |
2017-08-09 |
Kymab Ltd |
Bispecific antigen-binding molecules
|
US11597768B2
(en)
|
2017-06-26 |
2023-03-07 |
Beigene, Ltd. |
Immunotherapy for hepatocellular carcinoma
|
KR20230066126A
(ko)
|
2017-07-27 |
2023-05-12 |
알렉시온 파마슈티칼스, 인코포레이티드 |
고농도 항-c5 항체 제형
|
SG11202000764RA
(en)
|
2017-08-09 |
2020-02-27 |
Bioverativ Therapeutics Inc |
Nucleic acid molecules and uses thereof
|
BR112020003670A2
(pt)
|
2017-08-22 |
2020-09-01 |
Sanabio, Llc |
receptores de interferon solúveis e usos dos mesmos
|
SG11202000387YA
(en)
|
2017-08-25 |
2020-03-30 |
Five Prime Therapeutics Inc |
B7-h4 antibodies and methods of use thereof
|
US10538583B2
(en)
|
2017-10-31 |
2020-01-21 |
Staten Biotechnology B.V. |
Anti-APOC3 antibodies and compositions thereof
|
AU2018361957B2
(en)
|
2017-10-31 |
2023-05-25 |
Staten Biotechnology B.V. |
Anti-ApoC3 antibodies and methods of use thereof
|
CA3083118A1
(en)
|
2017-11-22 |
2019-05-31 |
Iovance Biotherapeutics, Inc. |
Expansion of peripheral blood lymphocytes (pbls) from peripheral blood
|
PL3717011T3
(pl)
|
2017-11-29 |
2023-03-27 |
Csl Limited |
Sposób leczenia lub zapobiegania uszkodzeniu niedokrwienno- reperfuzyjnemu
|
CN111801334B
(zh)
|
2017-11-29 |
2023-06-09 |
百济神州瑞士有限责任公司 |
使用包含btk抑制剂的组合治疗惰性或侵袭性b-细胞淋巴瘤
|
JP7422659B2
(ja)
|
2017-12-08 |
2024-01-26 |
アルジェニクス ビーブイ |
全身型重症筋無力症治療のためのFcRnアンタゴニストの使用
|
US11795226B2
(en)
|
2017-12-12 |
2023-10-24 |
Macrogenics, Inc. |
Bispecific CD16-binding molecules and their use in the treatment of disease
|
JP2021508104A
(ja)
|
2017-12-15 |
2021-02-25 |
アイオバンス バイオセラピューティクス,インコーポレイテッド |
腫瘍浸潤リンパ球の有益な投与を決定するシステム及び方法並びにその使用方法、並びに腫瘍浸潤リンパ球の有益な投与及びその使用方法
|
EP3498293A1
(de)
|
2017-12-15 |
2019-06-19 |
Institut National De La Sante Et De La Recherche Medicale (Inserm) |
Behandlung monogener erkrankungen mit einem anti-cd45rc-antikörper
|
US11802154B2
(en)
|
2017-12-20 |
2023-10-31 |
Alexion Pharmaceuticals, Inc. |
Humanized anti-CD200 antibodies and uses thereof
|
KR20200103761A
(ko)
|
2017-12-27 |
2020-09-02 |
브리스톨-마이어스 스큅 컴퍼니 |
항-cd40 항체 및 그의 용도
|
FR3076294B1
(fr)
|
2017-12-29 |
2022-01-28 |
Lab Francais Du Fractionnement |
Procede de purification d'anticorps a partir de lait brut
|
CA3087699A1
(en)
|
2018-01-05 |
2019-07-11 |
Corvidia Therapeutics, Inc. |
Methods for treating il-6 mediated inflammation without immunosuppression
|
CA3087569A1
(en)
|
2018-01-09 |
2019-07-18 |
Synthetic Biologics, Inc. |
Alkaline phosphatase agents for treatment of neurodevelopmental disorders
|
MX2020007429A
(es)
|
2018-01-12 |
2020-10-15 |
Takeda Pharmaceuticals Co |
Dosificacion subcutanea de anticuerpos anti grupo de diferenciacion 38 (cd38).
|
WO2019152692A1
(en)
|
2018-02-01 |
2019-08-08 |
Bioverativ Therapeutics, Inc. |
Use of lentiviral vectors expressing factor viii
|
MA51875A
(fr)
|
2018-02-13 |
2020-12-23 |
Iovance Biotherapeutics Inc |
Expansion de lymphocytes infiltrant les tumeurs (til) avec des antagonistes du récepteur a2a de l'adénosine et combinaisons thérapeutiques de til et d'antagonistes du récepteur a2a de l'adénosine
|
WO2019160976A1
(en)
|
2018-02-14 |
2019-08-22 |
Viela Bio, Inc. |
Antibodies to feline mcdonough sarcoma (fms)-like tyrosine kinase 3 receptor ligand (flt3l) and uses thereof for treating autoimmune and inflammatory diseases
|
US11685781B2
(en)
|
2018-02-15 |
2023-06-27 |
Macrogenics, Inc. |
Variant CD3-binding domains and their use in combination therapies for the treatment of disease
|
US11891432B2
(en)
|
2018-03-15 |
2024-02-06 |
Chugai Seiyaku Kabushiki Kaisha |
Anti-dengue virus antibodies having cross-reactivity to Zika virus and methods of use
|
EP3773686B1
(de)
|
2018-03-20 |
2023-06-07 |
Theriva Biologics, Inc. |
Alkalische phosphatasemittel zur behandlung von bestrahlungsstörungen
|
RU2020134294A
(ru)
*
|
2018-03-21 |
2022-04-22 |
ЭйЭлЭкс Онколоджи Инк. |
Антитела против сигнал-регуляторного белка альфа и способы их применения
|
WO2019180204A1
(en)
|
2018-03-23 |
2019-09-26 |
Université Libre de Bruxelles |
Wnt signaling agonist molecules
|
TW202003551A
(zh)
|
2018-03-28 |
2020-01-16 |
美商必治妥美雅史谷比公司 |
介白素-2/介白素-2受體阿法融合蛋白及其使用方法
|
WO2019186273A1
(en)
|
2018-03-28 |
2019-10-03 |
Takeda Pharmaceutical Company Limited |
Subcutaneous dosing of anti-cd38 antibodies
|
AU2019271148B2
(en)
|
2018-05-14 |
2023-07-06 |
Werewolf Therapeutics, Inc. |
Activatable interleukin-2 polypeptides and methods of use thereof
|
MX2020012248A
(es)
|
2018-05-14 |
2021-04-28 |
Werewolf Therapeutics Inc |
Polipeptidos de citocina activables y metodos de uso de los mismos.
|
KR20210013091A
(ko)
|
2018-05-16 |
2021-02-03 |
시에스엘 리미티드 |
가용성 보체 수용체 1형 변이체 및 이의 용도
|
TW202015723A
(zh)
|
2018-05-18 |
2020-05-01 |
美商百歐維拉提夫治療公司 |
治療a型血友病的方法
|
KR20210027352A
(ko)
|
2018-06-04 |
2021-03-10 |
바이오젠 엠에이 인코포레이티드 |
감소된 효과기 기능을 갖는 항-vla-4 항체
|
TW202016151A
(zh)
|
2018-06-09 |
2020-05-01 |
德商百靈佳殷格翰國際股份有限公司 |
針對癌症治療之多特異性結合蛋白
|
GB201809746D0
(en)
|
2018-06-14 |
2018-08-01 |
Berlin Chemie Ag |
Pharmaceutical combinations
|
SG11202012091WA
(en)
|
2018-06-15 |
2021-01-28 |
Proclara Biosciences Inc |
General amyloid interaction motif (gaim)
|
US20210275685A1
(en)
|
2018-06-26 |
2021-09-09 |
Immunogen, Inc. |
Immunoconjugates targeting adam9 and methods of use thereof
|
CN114903978A
(zh)
|
2018-07-03 |
2022-08-16 |
百时美施贵宝公司 |
Fgf-21配制品
|
WO2020014306A1
(en)
|
2018-07-10 |
2020-01-16 |
Immunogen, Inc. |
Met antibodies and immunoconjugates and uses thereof
|
TW202019966A
(zh)
|
2018-07-19 |
2020-06-01 |
美商再生元醫藥公司 |
雙特異性抗-BCMAx抗-CD3抗體及其用途
|
EP3833766A1
(de)
|
2018-08-09 |
2021-06-16 |
Bioverativ Therapeutics Inc. |
Nukleinsäuremoleküle und verwendungen davon zur nichtviralen gentherapie
|
US20210379153A1
(en)
|
2018-08-29 |
2021-12-09 |
Shattuck Labs, Inc. |
Combination therapies comprising sirp alpha-based chimeric proteins
|
JP7407822B2
(ja)
*
|
2018-08-30 |
2024-01-04 |
エイチシーダブリュー バイオロジックス インコーポレイテッド |
単鎖キメラポリペプチドおよびその使用
|
KR20210070287A
(ko)
|
2018-08-30 |
2021-06-14 |
에이치씨더블유 바이올로직스, 인크. |
다중-사슬 키메라 폴리펩타이드 및 이의 용도
|
JP7449292B2
(ja)
|
2018-08-30 |
2024-03-13 |
エイチシーダブリュー バイオロジックス インコーポレイテッド |
加齢関連障害の治療法
|
WO2020047520A1
(en)
*
|
2018-08-31 |
2020-03-05 |
Yale University |
Enpp1 polypeptides and methods of using same
|
TW202031273A
(zh)
|
2018-08-31 |
2020-09-01 |
美商艾歐凡斯生物治療公司 |
抗pd-1抗體難治療性之非小細胞肺癌(nsclc)病患的治療
|
MX2021003543A
(es)
|
2018-09-27 |
2021-06-23 |
Xilio Dev Inc |
Polipeptidos de citocinas enmascaradas.
|
AU2019352017A1
(en)
|
2018-10-03 |
2021-05-06 |
Staten Biotechnology B.V. |
Antibodies specific for human and cynomolgus ApoC3 and methods of use thereof
|
TW202029980A
(zh)
|
2018-10-26 |
2020-08-16 |
美商免疫遺傳股份有限公司 |
E p C A M 抗體、可活化抗體及免疫偶聯物以及其用途
|
EP3889179A4
(de)
|
2018-11-01 |
2022-10-12 |
Shandong New Time Pharmaceutical Co., Ltd. |
Bispezifischer antikörper und verwendung davon
|
SG11202104663PA
(en)
|
2018-11-05 |
2021-06-29 |
Iovance Biotherapeutics Inc |
Treatment of nsclc patients refractory for anti-pd-1 antibody
|
WO2020097627A1
(en)
|
2018-11-09 |
2020-05-14 |
University Of Massachusetts |
Anti-cfae antibodies and methods of use
|
BR112021009111A2
(pt)
|
2018-11-16 |
2021-08-24 |
Bristol-Myers Squibb Company |
Anticorpos anti-nkg2a e usos dos mesmos
|
US20220106400A1
(en)
|
2018-11-28 |
2022-04-07 |
Bristol-Myers Squibb Company |
Antibodies comprising modified heavy constant regions
|
WO2020116560A1
(ja)
|
2018-12-05 |
2020-06-11 |
株式会社バイカ・セラピュティクス |
抗体のFc領域改変体
|
WO2020118011A1
(en)
|
2018-12-06 |
2020-06-11 |
Alexion Pharmaceuticals, Inc. |
Anti-alk2 antibodies and uses thereof
|
WO2020114616A1
(en)
|
2018-12-07 |
2020-06-11 |
Tillotts Pharma Ag |
Topical treatment of immune checkpoint inhibitor induced diarrhoea, colitis or enterocolitis using antibodies and fragments thereof
|
WO2020115283A1
(en)
|
2018-12-07 |
2020-06-11 |
Baxalta GmbH |
Bispecific antibodies binding factor ixa and factor x
|
WO2020115281A1
(en)
|
2018-12-07 |
2020-06-11 |
Baxalta GmbH |
Proteinaceous molecules binding factor ixa and factor x
|
DK3723858T3
(da)
|
2018-12-21 |
2022-01-24 |
Kymab Ltd |
Fixaxfx bispecifik antistof med fælles let kæde
|
JP2022516881A
(ja)
|
2018-12-26 |
2022-03-03 |
キシリオ ディベロップメント インコーポレイテッド |
抗ctla4抗体およびその使用方法
|
KR20210111792A
(ko)
|
2018-12-28 |
2021-09-13 |
스팍스 테라퓨틱스 인크. |
암 및 다른 질환을 치료하기 위한 클라우딘 18.2에 특이적인 결합 분자, 이의 조성물 및 방법
|
CA3124352A1
(en)
|
2019-01-04 |
2020-07-09 |
Resolve Therapeutics, Llc |
Treatment of sjogren's disease with nuclease fusion proteins
|
SG11202107941TA
(en)
|
2019-01-23 |
2021-08-30 |
Encefa |
Cd31 competitors and uses thereof
|
MA55080A
(fr)
|
2019-02-26 |
2022-01-05 |
Inspirna Inc |
Anticorps anti-mertk à affinité élevée et utilisations associées
|
CN113840842A
(zh)
|
2019-02-26 |
2021-12-24 |
詹森生物科技公司 |
利用双特异性抗EGFR/c-Met抗体的联合疗法和患者分层
|
CA3131305A1
(en)
|
2019-03-01 |
2020-09-10 |
Iovance Biotherapeutics, Inc. |
Expansion of tumor infiltrating lymphocytes from liquid tumors and therapeutic uses thereof
|
CN113811332A
(zh)
|
2019-03-05 |
2021-12-17 |
普罗塞纳生物科学有限公司 |
治疗al淀粉样变性的方法
|
EP3943108A4
(de)
|
2019-03-19 |
2023-01-04 |
Chugai Seiyaku Kabushiki Kaisha |
Antigen-bindendes molekül mit antigen-bindender domäne mit veränderlicher bindungsaktivität gegenüber antigen in abhängigkeit von mta und bibliothek zur gewinnung der antigen-bindenden domäne
|
JP2022521850A
(ja)
|
2019-04-03 |
2022-04-12 |
ジェンザイム・コーポレーション |
断片化が低減した抗アルファベータtcr結合ポリペプチド
|
GB2589049C
(en)
|
2019-04-11 |
2024-02-21 |
argenx BV |
Anti-IgE antibodies
|
WO2020223565A1
(en)
|
2019-05-01 |
2020-11-05 |
Corvidia Therapeutics, Inc. |
Anti-il-6 antibody formulation
|
JOP20210304A1
(ar)
|
2019-05-14 |
2023-01-30 |
Janssen Biotech Inc |
علاجات مركبة باستخدام الأجسام المضادة ثنائية النوعية المضادة لمستقبل عامل نمو البشرة (EGFR)/ مستقبل عامل نمو خلايا الكبد (c-Met) ومثبطات كيناز التيروسين الخاصة بمستقبل عامل نمو البشرة (EGFR) من الجيل الثالث
|
CA3137512A1
(en)
|
2019-05-14 |
2020-11-19 |
Werewolf Therapeutics, Inc. |
Separation moieties and methods and use thereof
|
WO2020247852A1
(en)
|
2019-06-07 |
2020-12-10 |
Amgen Inc. |
Bispecific binding constructs
|
EP3980063A1
(de)
|
2019-06-07 |
2022-04-13 |
Argenx BVBA |
Pharmazeutische formulierungen von fcrn-inhibitoren zur subkutanen verabreichung
|
AR120054A1
(es)
|
2019-06-10 |
2022-02-02 |
Takeda Pharmaceuticals Co |
Politerapias con anticuerpos de cd-38
|
CN114174326A
(zh)
|
2019-06-18 |
2022-03-11 |
拜耳公司 |
长期稳定的肾上腺髓质素类似物及其用途
|
WO2020257639A1
(en)
|
2019-06-21 |
2020-12-24 |
HCW Biologics, Inc. |
Multi-chain chimeric polypeptides and uses thereof
|
TW202120686A
(zh)
|
2019-07-26 |
2021-06-01 |
美商舒爾人類基因療法公司 |
用以治療鐮狀細胞疾病之重組血基質加氧酶-1 (ho-1)
|
EP4010372A2
(de)
|
2019-08-06 |
2022-06-15 |
GlaxoSmithKline Intellectual Property Development Limited |
Biopharmazeutische zusammensetzungen und zugehörige verfahren
|
BR112022002761A2
(pt)
|
2019-08-12 |
2022-08-09 |
Aptevo Res & Development Llc |
Proteínas de ligação a 4-1bb e ox40 e composições e métodos relacionados, anticorpos contra 4-1bb, anticorpos contra ox40
|
AU2020329290A1
(en)
|
2019-08-13 |
2022-03-24 |
Elpis Biopharmaceuticals |
Engineered interleukin-2 receptor beta agonists
|
JP2022545741A
(ja)
|
2019-08-30 |
2022-10-28 |
アジェナス インコーポレイテッド |
抗cd96抗体およびその使用方法
|
WO2021067389A1
(en)
|
2019-09-30 |
2021-04-08 |
Bioverativ Therapeutics Inc. |
Lentiviral vector formulations
|
KR20220100611A
(ko)
|
2019-11-15 |
2022-07-15 |
엔테라 에스.알.엘. |
Tmem219 항체 및 이의 치료 용도
|
WO2021099574A1
(en)
|
2019-11-21 |
2021-05-27 |
Enthera S.R.L. |
Igfbp3 antibodies and therapeutic uses thereof
|
US20230025129A1
(en)
|
2019-11-29 |
2023-01-26 |
Kymab Limited |
Treatment for physiological iron overload
|
PE20221661A1
(es)
|
2019-12-18 |
2022-10-26 |
Hoffmann La Roche |
Anticuerpos anti-ccl2 biespecificos
|
BR112022013554A2
(pt)
|
2020-01-08 |
2022-09-06 |
argenx BV |
Métodos para tratar distúrbios do pênfigo
|
WO2021158938A1
(en)
|
2020-02-06 |
2021-08-12 |
Bristol-Myers Squibb Company |
Il-10 and uses thereof
|
EP3868396A1
(de)
|
2020-02-20 |
2021-08-25 |
Enthera S.R.L. |
Inhibitoren und verwendungen davon
|
MX2022010538A
(es)
|
2020-02-28 |
2022-09-21 |
Genzyme Corp |
Polipeptidos de union modificados para conjugacion optimizada con farmacos.
|
US11365239B2
(en)
|
2020-03-20 |
2022-06-21 |
Tsb Therapeutics (Beijing) Co., Ltd. |
Anti-SARS-COV-2 antibodies and uses thereof
|
WO2021191836A1
(en)
|
2020-03-27 |
2021-09-30 |
Glaxosmithkline Biologicals Sa |
Hcvm pentamer binding antibodies
|
WO2021202463A1
(en)
|
2020-03-30 |
2021-10-07 |
Danisco Us Inc |
Anti-rsv antibodies
|
JP2023522102A
(ja)
|
2020-04-20 |
2023-05-26 |
ジェンザイム・コーポレーション |
ヒト化抗補体Bb因子抗体およびその使用
|
AU2021259628A1
(en)
|
2020-04-24 |
2023-01-05 |
Millennium Pharmaceuticals, Inc. |
Anti-CD19 antibodies and uses thereof
|
WO2021231732A1
(en)
|
2020-05-15 |
2021-11-18 |
Bristol-Myers Squibb Company |
Antibodies to garp
|
CN115697491A
(zh)
|
2020-05-17 |
2023-02-03 |
阿斯利康(英国)有限公司 |
Sars-cov-2抗体及其选择和使用方法
|
WO2021234160A2
(en)
|
2020-05-22 |
2021-11-25 |
Formycon Ag |
Ace2 fusion proteins and uses thereof
|
CA3184351A1
(en)
|
2020-06-04 |
2021-12-09 |
Amgen Inc. |
Bispecific binding constructs
|
WO2021251438A1
(ja)
|
2020-06-10 |
2021-12-16 |
株式会社バイカ・セラピュティクス |
エリスロポエチンポリペプチドを含む融合タンパク質
|
CA3186143A1
(en)
|
2020-06-17 |
2021-12-23 |
Medimmune Limited |
Heterodimeric relaxin fusions and uses thereof
|
CN116670285A
(zh)
|
2020-06-23 |
2023-08-29 |
江苏康缘药业股份有限公司 |
抗cd38抗体及其用途
|
JP2023532019A
(ja)
*
|
2020-06-23 |
2023-07-26 |
マドン アドバイザーズ エルエルシー |
抗ccr5モノクローナル抗体ベースの組成物および方法
|
CA3165342A1
(en)
|
2020-06-29 |
2022-01-06 |
James Arthur Posada |
Treatment of sjogren's syndrome with nuclease fusion proteins
|
EP4175650A1
(de)
|
2020-07-06 |
2023-05-10 |
Kiromic BioPharma, Inc. |
Mesothelinisoformbindende moleküle und chimäre pd1-rezeptormoleküle, zellen damit und verwendungen davon
|
AR122933A1
(es)
|
2020-07-10 |
2022-10-19 |
Novo Nordisk As |
Métodos para tratar la enfermedad cardiovascular
|
AU2021320870A1
(en)
|
2020-08-06 |
2023-04-06 |
Bioverativ Usa Inc. |
Inflammatory cytokines and fatigue in subject with a complement mediated disease
|
KR20230045613A
(ko)
|
2020-08-10 |
2023-04-04 |
아스트라제네카 유케이 리미티드 |
Covid-19의 치료 및 예방을 위한 sars-cov-2 항체
|
US11725052B2
(en)
|
2020-08-18 |
2023-08-15 |
Cephalon Llc |
Anti-PAR-2 antibodies and methods of use thereof
|
EP4208474A2
(de)
|
2020-09-01 |
2023-07-12 |
Takeda Pharmaceutical Company Limited |
Interleukin-2-muteine und verwendungen davon
|
KR20230084497A
(ko)
|
2020-09-11 |
2023-06-13 |
메디뮨 리미티드 |
치료용 b7-h4 결합 분자
|
TW202229312A
(zh)
|
2020-09-29 |
2022-08-01 |
德商英麥提克生物技術股份有限公司 |
由非hla-a*02顯露以用於不同類型癌症之免疫治療的醯胺化肽及其脫醯胺化對應物
|
DE102020125465A1
(de)
|
2020-09-29 |
2022-03-31 |
Immatics Biotechnologies Gmbh |
Amidierte Peptide und ihre deamidierten Gegenstücke, die durch nicht-HLA-A*02-Moleküle präsentiert werden, zur Verwendung in der Immuntherapie gegen verschiedene Krebsarten
|
DE102020125457A1
(de)
|
2020-09-29 |
2022-03-31 |
Immatics Biotechnologies Gmbh |
Amidierte Peptide und ihre deamidierten Gegenstücke, die durch HLA-A*02-Moleküle präsentiert werden, zur Verwendung in der Immuntherapie gegen verschiedene Krebsarten
|
JP2023546359A
(ja)
|
2020-10-06 |
2023-11-02 |
アイオバンス バイオセラピューティクス,インコーポレイテッド |
腫瘍浸潤リンパ球療法によるnsclc患者の治療
|
WO2022076606A1
(en)
|
2020-10-06 |
2022-04-14 |
Iovance Biotherapeutics, Inc. |
Treatment of nsclc patients with tumor infiltrating lymphocyte therapies
|
CA3195512A1
(en)
*
|
2020-10-14 |
2022-04-21 |
Vahe Bedian |
Compositions and methods for treatment of thyroid eye disease
|
EP4204091A2
(de)
|
2020-10-29 |
2023-07-05 |
Formycon AG |
Ace2-fusionsproteine und verwendungen davon
|
WO2022108627A1
(en)
|
2020-11-18 |
2022-05-27 |
Kiromic Biopharma, Inc.Kiromic Biopharma, Inc. |
Gamma-delta t cell manufacturing processes and chimeric pd1 receptor molecules
|
JP2023551907A
(ja)
|
2020-12-01 |
2023-12-13 |
アプティーボ リサーチ アンド デベロップメント エルエルシー |
腫瘍関連抗原及びcd3結合タンパク質、関連する組成物、及び方法
|
JP2023553384A
(ja)
|
2020-12-03 |
2023-12-21 |
アムジエン・インコーポレーテツド |
複数の結合ドメインを有する免疫グロブリン構築物
|
WO2022125566A1
(en)
*
|
2020-12-08 |
2022-06-16 |
Janux Therapeutics, Inc. |
Half-life extending compositions and methods
|
US11555078B2
(en)
|
2020-12-09 |
2023-01-17 |
Janux Therapeutics, Inc. |
Compositions and methods related to tumor activated antibodies targeting PSMA and effector cell antigens
|
TW202241468A
(zh)
|
2020-12-11 |
2022-11-01 |
美商艾歐凡斯生物治療公司 |
用腫瘤浸潤性淋巴球療法與braf抑制劑及/或mek抑制劑組合治療癌症患者
|
CA3202483A1
(en)
|
2020-12-17 |
2022-06-23 |
Maria Fardis |
Treatment with tumor infiltrating lymphocyte therapies in combination with ctla-4 and pd-1 inhibitors
|
WO2022133149A1
(en)
|
2020-12-17 |
2022-06-23 |
Iovance Biotherapeutics, Inc. |
Treatment of cancers with tumor infiltrating lymphocytes
|
JP2023554456A
(ja)
|
2020-12-18 |
2023-12-27 |
チューハイ トリノマブ ファーマシューティカル カンパニー リミテッド |
呼吸器合胞体ウイルスに特異的に結合する分子
|
EP4271791A2
(de)
|
2020-12-31 |
2023-11-08 |
Iovance Biotherapeutics, Inc. |
Vorrichtungen und verfahren zur automatisierten herstellung von tumorinfiltrierenden lymphozyten
|
TW202241925A
(zh)
|
2021-01-15 |
2022-11-01 |
德商英麥提克生物技術股份有限公司 |
用於不同類型癌症免疫治療的hla展示肽
|
JP2024504372A
(ja)
|
2021-01-22 |
2024-01-31 |
エルピス・バイオファーマシューティカルズ |
抗pd-l1モノクローナル抗体及びインターロイキン15(il-15)、インターロイキン15受容体15アルファまたはインターロイキン2との融合タンパク質
|
CA3206549A1
(en)
|
2021-01-29 |
2022-08-04 |
Frederick G. Vogt |
Methods of making modified tumor infiltrating lymphocytes and their use in adoptive cell therapy
|
CA3209364A1
(en)
|
2021-03-01 |
2022-09-09 |
Jennifer O'neil |
Combination of masked ctla4 and pd1/pdl1 antibodies for treating cancer
|
WO2022187270A1
(en)
|
2021-03-01 |
2022-09-09 |
Xilio Development, Inc. |
Combination of ctla4 and pd1/pdl1 antibodies for treating cancer
|
CA3205815A1
(en)
|
2021-03-03 |
2022-09-09 |
Alwin REITER |
Formulations of ace2 fc fusion proteins
|
JP2024509184A
(ja)
|
2021-03-05 |
2024-02-29 |
アイオバンス バイオセラピューティクス,インコーポレイテッド |
腫瘍保存及び細胞培養組成物
|
EP4308691A1
(de)
|
2021-03-19 |
2024-01-24 |
Iovance Biotherapeutics, Inc. |
Verfahren zur expansion von tumorinfiltrierenden lymphozyten (til) im zusammenhang mit der cd39/cd69-auswahl und gen-knockout in tils
|
AR125199A1
(es)
|
2021-03-23 |
2023-06-21 |
Iovance Biotherapeutics Inc |
Edición génica cish de linfocitos infiltrantes de tumores y usos de los mismos en inmunoterapia
|
WO2022204564A2
(en)
|
2021-03-25 |
2022-09-29 |
Iovance Biotherapeutics, Inc. |
Methods and compositions for t-cell coculture potency assays and use with cell therapy products
|
WO2022204581A2
(en)
|
2021-03-26 |
2022-09-29 |
Scholar Rock, Inc. |
Tgf-beta inhibitors and use thereof
|
WO2022207785A1
(en)
|
2021-03-31 |
2022-10-06 |
Kymab Limited |
Antibodies to gfral
|
TW202304508A
(zh)
|
2021-03-31 |
2023-02-01 |
美商百歐維拉提夫美國公司 |
減少冷凝集素疾病患者之手術相關溶血
|
KR20230165285A
(ko)
|
2021-03-31 |
2023-12-05 |
캠브리지 엔터프라이즈 리미티드 |
Gdf15 신호전달의 치료적 억제제
|
WO2022215054A1
(en)
|
2021-04-09 |
2022-10-13 |
Takeda Pharmaceutical Company Limited |
Antibodies targeting complement factor d and uses therof
|
WO2022225981A2
(en)
|
2021-04-19 |
2022-10-27 |
Iovance Biotherapeutics, Inc. |
Chimeric costimulatory receptors, chemokine receptors, and the use of same in cellular immunotherapies
|
IL307939A
(en)
|
2021-04-26 |
2023-12-01 |
Millennium Pharm Inc |
Anti-CLEC12A antibodies and uses thereof
|
CA3214355A1
(en)
|
2021-04-26 |
2022-11-03 |
Antara Banerjee |
Anti-adgre2 antibodies and uses thereof
|
WO2022245754A1
(en)
|
2021-05-17 |
2022-11-24 |
Iovance Biotherapeutics, Inc. |
Pd-1 gene-edited tumor infiltrating lymphocytes and uses of same in immunotherapy
|
WO2022248870A1
(en)
|
2021-05-28 |
2022-12-01 |
Glaxosmithkline Intellectual Property Development Limited |
Combination therapies for treating cancer
|
WO2022256723A2
(en)
|
2021-06-03 |
2022-12-08 |
Scholar Rock, Inc. |
Tgf-beta inhibitors and therapeutic use thereof
|
WO2022263357A1
(en)
|
2021-06-14 |
2022-12-22 |
Argenx Iip Bv |
Anti-il-9 antibodies and methods of use thereof
|
KR20240021859A
(ko)
|
2021-06-18 |
2024-02-19 |
에프. 호프만-라 로슈 아게 |
이중특이적 항-ccl2 항체
|
WO2022271867A1
(en)
|
2021-06-23 |
2022-12-29 |
Scholar Rock, Inc. |
A myostatin pathway inhibitor in combination with a glp-1 pathway activator for use in treating metabolic disorders
|
CA3226111A1
(en)
|
2021-07-22 |
2023-01-26 |
Iovance Biotherapeutics, Inc. |
Method for cryopreservation of solid tumor fragments
|
CA3226942A1
(en)
|
2021-07-28 |
2023-02-02 |
Iovance Biotherapeutics, Inc. |
Treatment of cancer patients with tumor infiltrating lymphocyte therapies in combination with kras inhibitors
|
TW202323822A
(zh)
|
2021-08-03 |
2023-06-16 |
英商葛蘭素史密斯克藍智慧財產發展有限公司 |
生藥組合物及穩定同位素標記肽之圖譜定位方法
|
WO2023023503A1
(en)
*
|
2021-08-16 |
2023-02-23 |
Yale University |
Interleukin-12 variants and methods of use
|
WO2023021169A1
(en)
|
2021-08-20 |
2023-02-23 |
Intervet International B.V. |
Antibodies and igg fusion proteins with an extended half-life
|
AU2022332285A1
(en)
|
2021-08-23 |
2024-02-15 |
Immunitas Therapeutics, Inc. |
Anti-cd161 antibodies and uses thereof
|
TW202328439A
(zh)
|
2021-09-09 |
2023-07-16 |
美商艾歐凡斯生物治療公司 |
使用pd-1 talen基因減弱生成til產物之方法
|
WO2023049862A1
(en)
|
2021-09-24 |
2023-03-30 |
Iovance Biotherapeutics, Inc. |
Expansion processes and agents for tumor infiltrating lymphocytes
|
WO2023056362A1
(en)
|
2021-09-30 |
2023-04-06 |
Seagen Inc. |
B7-h4 antibody-drug conjugates for the treatment of cancer
|
WO2023057893A1
(en)
|
2021-10-05 |
2023-04-13 |
Glaxosmithkline Intellectual Property Development Limited |
Combination therapies for treating cancer
|
WO2023068382A2
(en)
|
2021-10-20 |
2023-04-27 |
Takeda Pharmaceutical Company Limited |
Compositions targeting bcma and methods of use thereof
|
US20230187042A1
(en)
|
2021-10-27 |
2023-06-15 |
Iovance Biotherapeutics, Inc. |
Systems and methods for coordinating manufacturing of cells for patient-specific immunotherapy
|
TW202342095A
(zh)
|
2021-11-05 |
2023-11-01 |
英商阿斯特捷利康英國股份有限公司 |
用於治療和預防covid—19之組成物
|
WO2023086803A1
(en)
|
2021-11-10 |
2023-05-19 |
Iovance Biotherapeutics, Inc. |
Methods of expansion treatment utilizing cd8 tumor infiltrating lymphocytes
|
WO2023091968A1
(en)
|
2021-11-17 |
2023-05-25 |
Disc Medicine, Inc. |
Methods for treating anemia of kidney disease
|
WO2023094507A1
(en)
|
2021-11-24 |
2023-06-01 |
Formycon Ag |
Improved ace2 fusion proteins
|
WO2023094571A1
(en)
|
2021-11-25 |
2023-06-01 |
Formycon Ag |
Stabilization of ace2 fusion proteins
|
WO2023111112A1
(en)
|
2021-12-15 |
2023-06-22 |
Medimmune Limited |
Treatment using heterodimeric relaxin fusions
|
WO2023114951A1
(en)
|
2021-12-17 |
2023-06-22 |
Viiv Healthcare Company |
Combination therapies for hiv infections and uses thereof
|
WO2023139107A1
(en)
|
2022-01-18 |
2023-07-27 |
argenx BV |
Galectin-10 antibodies
|
WO2023147488A1
(en)
|
2022-01-28 |
2023-08-03 |
Iovance Biotherapeutics, Inc. |
Cytokine associated tumor infiltrating lymphocytes compositions and methods
|
WO2023147486A1
(en)
|
2022-01-28 |
2023-08-03 |
Iovance Biotherapeutics, Inc. |
Tumor infiltrating lymphocytes engineered to express payloads
|
TW202348252A
(zh)
|
2022-02-16 |
2023-12-16 |
英商梅迪繆思有限公司 |
用治療性結合分子治療癌症的組合療法
|
WO2023168352A1
(en)
|
2022-03-03 |
2023-09-07 |
Yale University |
Humanized 3e10 antibodies, variants, and antigen binding fragments thereof
|
WO2023169896A1
(en)
|
2022-03-09 |
2023-09-14 |
Astrazeneca Ab |
BINDING MOLECULES AGAINST FRα
|
WO2023170216A1
(en)
|
2022-03-11 |
2023-09-14 |
Astrazeneca Ab |
A SCORING METHOD FOR AN ANTI-FRα ANTIBODY-DRUG CONJUGATE THERAPY
|
WO2023196877A1
(en)
|
2022-04-06 |
2023-10-12 |
Iovance Biotherapeutics, Inc. |
Treatment of nsclc patients with tumor infiltrating lymphocyte therapies
|
WO2023201369A1
(en)
|
2022-04-15 |
2023-10-19 |
Iovance Biotherapeutics, Inc. |
Til expansion processes using specific cytokine combinations and/or akti treatment
|
US20230348604A1
(en)
|
2022-04-29 |
2023-11-02 |
23Andme, Inc. |
Antigen binding proteins
|
WO2023209177A1
(en)
|
2022-04-29 |
2023-11-02 |
Astrazeneca Uk Limited |
Sars-cov-2 antibodies and methods of using the same
|
KR20230156844A
(ko)
|
2022-05-02 |
2023-11-14 |
노보 노르디스크 에이/에스 |
고농도 조성물 및 피하 투여에 적합한 신규한 항-angptl3 항체
|
WO2023220597A1
(en)
|
2022-05-10 |
2023-11-16 |
Elpis Biopharmaceuticals |
Engineered interleukin-2 receptor beta reduced-binding agonist
|
WO2023220608A1
(en)
|
2022-05-10 |
2023-11-16 |
Iovance Biotherapeutics, Inc. |
Treatment of cancer patients with tumor infiltrating lymphocyte therapies in combination with an il-15r agonist
|
WO2023242372A1
(en)
|
2022-06-15 |
2023-12-21 |
argenx BV |
Fcrn/hsa binding molecules and methods of use
|
WO2023245048A1
(en)
|
2022-06-15 |
2023-12-21 |
Bioverativ Usa Inc. |
Anti-complement c1s antibody formulation
|
US20240025978A1
(en)
|
2022-06-24 |
2024-01-25 |
Bioverativ Usa Inc. |
Methods for treating complement-mediated diseases
|
WO2024011114A1
(en)
|
2022-07-06 |
2024-01-11 |
Iovance Biotherapeutics, Inc. |
Devices and processes for automated production of tumor infiltrating lymphocytes
|
WO2024015830A1
(en)
|
2022-07-12 |
2024-01-18 |
Cytomx Therapeutics, Inc. |
Epcam immunoconjugates and uses thereof
|
US20240034780A1
(en)
|
2022-07-22 |
2024-02-01 |
Flagship Pioneering Innovations Vi, Llc |
Antigen Binding Molecules Targeting Thymic Stromal Lymphopoietin (TSLP)
|
WO2024026386A1
(en)
|
2022-07-27 |
2024-02-01 |
Cephalon Llc |
Anti-tl1a antibody formulations
|
WO2024026395A1
(en)
|
2022-07-27 |
2024-02-01 |
Cephalon Llc |
Anti-tl1a antibodies for the treatment of ulcerative colitis and crohn's disease
|
WO2024026474A1
(en)
|
2022-07-29 |
2024-02-01 |
Regeneron Pharmaceuticals, Inc. |
Compositions and methods for transferrin receptor (tfr)-mediated delivery to the brain and muscle
|
WO2024026494A1
(en)
|
2022-07-29 |
2024-02-01 |
Regeneron Pharmaceuticals, Inc. |
Viral particles retargeted to transferrin receptor 1
|
US20240052051A1
(en)
|
2022-07-29 |
2024-02-15 |
Regeneron Pharmaceuticals, Inc. |
Anti-tfr:payload fusions and methods of use thereof
|
WO2024030758A1
(en)
|
2022-08-01 |
2024-02-08 |
Iovance Biotherapeutics, Inc. |
Chimeric costimulatory receptors, chemokine receptors, and the use of same in cellular immunotherapies
|
WO2024038193A1
(en)
|
2022-08-18 |
2024-02-22 |
Immunocore Limited |
Multi-domain binding molecules
|
WO2024038183A1
(en)
|
2022-08-18 |
2024-02-22 |
Immunocore Limited |
Multi-domain binding molecules
|
WO2024042112A1
(en)
|
2022-08-25 |
2024-02-29 |
Glaxosmithkline Intellectual Property Development Limited |
Antigen binding proteins and uses thereof
|
WO2024050421A2
(en)
|
2022-08-30 |
2024-03-07 |
Flagship Pioneering Innovations Vi, Llc |
Antigen binding molecules targeting programmed cell death protein 1 (pd-1)
|